Antisense compounds targeting genes associated with fibronectin

ABSTRACT

The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0197USC1SEQ.txt, created Oct. 18, 2017, which is 264 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Fibronectin is a high-molecular weight glycoprotein of the extracellular matrix that binds to membrane-spanning receptor integrin proteins. Fibronectin has been implicated in a number of fibrotic disorders, including renal fibrosis. Alternative splicing of fibronectin pre-mRNA leads to the creation of fibronectin mRNA having a different combination of exons, which in turn leads to the creation of several isoforms of fibronectin protein. In certain instances, alternative splicing of the fibronectin gene results in a fibronectin protein isoform containing the extra type III domain A (EDA). Fibronectin containing extra type III domain A (EDA) is implicated in the formation of fibrosis. See, e.g., Muro et al., An Essential Role for Fibronectin Extra Type III Domain A in Pulmonary Fibrosis, American Journal of Respitory and Critical Care Medicine, Vol. 177, 638 (2008).

Antisense compounds have been used to modulate target nucleic acids. Antisense compounds comprising a variety of chemical modifications and motifs have been reported. In certain instances, such compounds are useful as research tools, diagnostic reagents, and as therapeutic agents. In certain instances antisense compounds have been shown to modulate protein expression by binding to a target messenger RNA (mRNA) encoding the protein. In certain instances, such binding of an antisense compound to its target mRNA results in cleavage of the mRNA. Antisense compounds that modulate processing of a pre-mRNA have also been reported. Such antisense compounds alter splicing, interfere with polyadenylation or prevent formation of the 5′-cap of a pre-mRNA.

Certain antisense compounds have been described previously. See for example U.S. Pat. No. 7,399,845 and published International Patent Application No. WO 2008/049085, which are hereby incorporated by reference herein in their entirety.

SUMMARY OF THE INVENTION

In certain embodiments, the present invention provides compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides are complementary to a fibronectin transcript. In certain such embodiments, oligonucleotides are complementary to a target region of the fibronectin transcript comprising the EDA exon. In certain such embodiments, oligonucleotides are complementary to a target region of the fibronectin transcript comprising an intron adjacent to the EDA exon. In certain such embodiments, oligonucleotides are complementary to a target region of the fibronectin transcript comprising an intron adjacent to the EDA exon and downstream of the EDA exon. In certain such embodiments, oligonucleotides are complementary to a target region of the fibronectin transcript comprising an intron adjacent to the EDA exon and upstream of the EDA exon. In certain embodiments, the fibronectin transcript comprises an exonic splice enhancer for the EDA exon. In certain embodiments, the fibronectin transcript comprises an exonic splice silencer for the EDA exon. In certain embodiments, oligonucleotides inhibit inclusion of the EDA exon. In certain embodiments, oligonucleotides promote skipping of the of the EDA exon. In certain such embodiments, fibronectin mRNA without EDA mRNA is increased. In certain such embodiments, fibronectin protein without EDA is increased.

The present disclosure provides the following non-limiting numbered embodiments:

Embodiment 1

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a fibronectin transcript.

Embodiment 2

The compound of embodiment 1, wherein the complementary region of the modified oligonucleotide is 100% complementary to the target region.

Embodiment 3

The compound of embodiment 1 or 2, wherein the complementary region of the modified oligonucleotide comprises at least 10 contiguous nucleobases.

Embodiment 4

The compound of embodiment 1 or 2, wherein the complementary region of the modified oligonucleotide comprises at least 12 contiguous nucleobases.

Embodiment 5

The compound of embodiment 1 or 2, wherein the complementary region of the modified oligonucleotide comprises at least 15 contiguous nucleobases.

Embodiment 6

The compound of embodiment 1 or 2, wherein the complementary region of the modified oligonucleotide comprises at least 18 contiguous nucleobases.

Embodiment 7

The compound of embodiment 1 or 2, wherein the complementary region of the modified oligonucleotide comprises at least 20 contiguous nucleobases.

Embodiment 8

The compound of any of embodiments 1-5, wherein the nucleobase sequence of the oligonucleotide is at least 80% complementary to an equal-length region of the fibronectin transcript, as measured over the entire length of the oligonucleotide.

Embodiment 9

The compound of any of embodiments 1-5, wherein the nucleobase sequence of the oligonucleotide is at least 90% complementary to an equal-length region of the fibronectin transcript, as measured over the entire length of the oligonucleotide.

Embodiment 10

The compound of any of embodiments 1-5, wherein the nucleobase sequence of the oligonucleotide is 100% complementary to an equal-length region of the fibronectin transcript, as measured over the entire length of the oligonucleotide.

Embodiment 11

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55469 and nucleobase 55790 of SEQ ID NO.: 1.

Embodiment 12

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55469 and nucleobase 55511 of SEQ ID NO.: 1.

Embodiment 13

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55511 and nucleobase 55732 of SEQ ID NO.: 1.

Embodiment 14

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55732 and nucleobase 55790 of SEQ ID NO.: 1.

Embodiment 15

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55491 and nucleobase 55511 of SEQ ID NO.: 1.

Embodiment 16

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55490 and nucleobase 55510 of SEQ ID NO.: 1.

Embodiment 17

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55491 and nucleobase 55513 of SEQ ID NO.: 1.

Embodiment 18

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55536 and nucleobase 55555 of SEQ ID NO.: 1.

Embodiment 19

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55576 and nucleobase 55600 of SEQ ID NO.: 1.

Embodiment 20

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55604 and nucleobase 55623 of SEQ ID NO.: 1.

Embodiment 21

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55610 and nucleobase 55697 of SEQ ID NO.: 1.

Embodiment 22

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55701 and nucleobase 55737 of SEQ ID NO.: 1.

Embodiment 23

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55738 and nucleobase 55757 of SEQ ID NO.: 1.

Embodiment 24

The compound of any of embodiments 1-10, wherein the target region is within nucleobase 55753 and nucleobase 55781 of SEQ ID NO.: 1.

Embodiment 25

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 5.

Embodiment 26

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 9.

Embodiment 27

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 13.

Embodiment 28

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 14.

Embodiment 29

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 15.

Embodiment 30

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 18.

Embodiment 31

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 22.

Embodiment 32

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 66.

Embodiment 33

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 67.

Embodiment 34

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises any of SEQ ID NOs: 5 to 24.

Embodiment 35

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises any of SEQ ID NOs: 30 to 90.

Embodiment 36

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 413.

Embodiment 37

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises SEQ ID NO: 346.

Embodiment 38

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises any of SEQ ID NOs: 104 to 176.

Embodiment 39

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises any of SEQ ID NOs: 177 to 329.

Embodiment 40

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises any of SEQ ID NOs: 403 to 435.

Embodiment 41

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises any of SEQ ID NOs: 105, 87, 126, 133, 134, 140, 141, 147, 149, 157, 159, 190, 223, 238, 244, 268, 285, 300, 302, 303, 308, 319, 327, 381, 382, 339, 346, 348, 364, 365, 367, 368, 369, 370, 268, 276, 280, 406, 407, 412, 413, and 324.

Embodiment 42

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide has a nucleobase sequence comprising CTTCTTCT.

Embodiment 43

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide has a nucleobase sequence comprising GTTCC.

Embodiment 44

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide has a nucleobase sequence comprising GTCCC.

Embodiment 45

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises a sugar motif described by Formula I as follows:

[(A)-(B)₂-(A)]_(n)

wherein:

each A is independently a bicyclic nucleoside;

each B is independently a 2′-substituted nucleoside or a 2′-deoxynucleoside; and

n is an integer from 3-6.

Embodiment 46

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises a sugar motif described by Formula II as follows:

(A)₂-[(B)₂-(A)]_(n)-(A)

wherein:

each A is independently a bicyclic nucleoside;

each B is independently a 2′-substituted nucleoside or a 2′-deoxynucleoside; and

n is an integer from 3-6.

Embodiment 47

The compound of any of embodiments 1-24, wherein the antisense oligonucleotide comprises a sugar motif described by Formula III as follows:

(A)₂-[(B)₂-(A)]_(n)

wherein:

each A is independently a bicyclic nucleoside;

each B is independently a 2′-substituted nucleoside or a 2′-deoxynucleoside; and

n is an integer from 3-6.

Embodiment 48

The compound of any of embodiments 45 to 47, wherein each A comprises a bicyclic nucleoside selected from among LNA and cEt.

Embodiment 49

The compound of any of embodiments 45 to 47, wherein each A comprises a cEt modification.

Embodiment 50

The compound of any of embodiments 45 to 47, wherein each A comprises an LNA modification.

Embodiment 51

The compound of any of embodiments 45 to 50, wherein each B comprises a 2′-substituted nucleoside having a 2′-modification selected from among 2′-OMe, 2′-F, and 2′-MOE.

Embodiment 52

The compound embodiment 51, wherein the 2′-modification is a 2′-MOE modification.

Embodiment 53

The compound of any of embodiments 45 to 50, wherein each B comprises a 2′-deoxynucleoside.

Embodiment 54

The compound of any of embodiments 1-44, wherein the modified oligonucleotide comprises at least one modified nucleoside.

Embodiment 55

The compound of embodiment 54, wherein at least one modified nucleoside comprises a modified sugar moiety.

Embodiment 56

The compound of embodiment 55, wherein at least one modified sugar moiety is a 2′-substituted sugar moiety.

Embodiment 57

The compound of embodiment 56, wherein the 2′-substituent of at least one 2′-substituted sugar moiety is selected from among: 2′-OMe, 2′-F, and 2′-MOE.

Embodiment 58

The compound of embodiment 57, wherein the 2′-substituent of at least one 2′-substituted sugar moiety is a 2′-MOE.

Embodiment 59

The compound of any of embodiments 54-56, wherein at least one modified sugar moiety is a bicyclic sugar moiety.

Embodiment 60

The compound of embodiment 59, wherein at least one bicyclic sugar moiety is LNA or cEt.

Embodiment 61

The compound of any of embodiments 54-60, wherein at least one sugar moiety is a sugar surrogate.

Embodiment 62

The compound of embodiment 61, wherein at least one sugar surrogate is a morpholino.

Embodiment 63

The compound of embodiment 61, wherein at least one sugar surrogate is a modified morpholino.

Embodiment 64

The compound of any of embodiment 1-63, wherein the modified oligonucleotide comprises at least 5 modified nucleosides, each independently comprising a modified sugar moiety.

Embodiment 65

The compound of embodiment 64, wherein the modified oligonucleotide comprises at least 10 modified nucleosides, each independently comprising a modified sugar moiety.

Embodiment 66

The compound of embodiment 64, wherein the modified oligonucleotide comprises at least 15 modified nucleosides, each independently comprising a modified sugar moiety.

Embodiment 67

The compound of any of embodiments 1 to 44 or 54 to 66, wherein each nucleoside of the modified oligonucleotide is a modified nucleoside, each independently comprising a modified sugar moiety Embodiment 68. The compound of any of embodiments 1-67, wherein the modified oligonucleotide comprises at least two modified nucleosides comprising modified sugar moieties that are the same as one another.

Embodiment 69

The compound of any of embodiments 1-68, wherein the modified oligonucleotide comprises at least two modified nucleosides comprising modified sugar moieties that are different from one another.

Embodiment 70

The compound of any of embodiments 1-69, wherein the modified oligonucleotide comprises a modified region of at least 5 contiguous modified nucleosides.

Embodiment 71

The compound of any of embodiments 1 to 44 or 54 to 70, wherein the modified oligonucleotide comprises a modified region of at least 10 contiguous modified nucleosides.

Embodiment 72

The compound of any of embodiments 1 to 44 or 54 to 70, wherein the modified oligonucleotide comprises a modified region of at least 15 contiguous modified nucleosides.

Embodiment 73

The compound of any of embodiments 1 to 44 or 54 to 70, wherein the modified oligonucleotide comprises a modified region of at least 20 contiguous modified nucleosides.

Embodiment 74

The compound of any of embodiments 70-73, wherein each modified nucleoside of the modified region has a modified sugar moiety independently selected from among: 2′-F, 2′-OMe, 2′-MOE, cEt, LNA, morpholino, and modified morpholino.

Embodiment 75

The compound of any of embodiments 70-73, wherein the modified nucleosides of the modified region each comprise the same modification as one another.

Embodiment 76

The compound of embodiment 75, wherein the modified nucleosides of the modified region each comprise the same 2′-substituted sugar moiety.

Embodiment 77

The compound of embodiment 75, wherein the 2′-substituted sugar moiety of the modified nucleosides of the region of modified nucleosides is selected from 2′-F, 2′-OMe, and 2′-MOE.

Embodiment 78

The compound of embodiment 77, wherein the 2′-substituted sugar moiety of the modified nucleosides of the region of modified nucleosides is 2′-MOE.

Embodiment 79

The compound of embodiment 75, wherein the modified nucleosides of the region of modified nucleosides each comprise the same bicyclic sugar moiety.

Embodiment 80

The compound of embodiment 79, wherein the bicyclic sugar moiety of the modified nucleosides of the region of modified nucleosides is selected from LNA and cEt.

Embodiment 81

The compound of embodiment 75, wherein the modified nucleosides of the region of modified nucleosides each comprises a sugar surrogate.

Embodiment 82

The compound of embodiment 81, wherein the sugar surrogate of the modified nucleosides of the region of modified nucleosides is a morpholino.

Embodiment 83

The compound of embodiment 81, wherein the sugar surrogate of the modified nucleosides of the region of modified nucleosides is a modified morpholino.

Embodiment 84

The compound of any of embodiments 1-83, wherein the modified nucleotide comprises no more than 4 contiguous naturally occurring nucleosides.

Embodiment 85

The compound of any of embodiments 1 to 44 or 54 to 85, wherein each nucleoside of the modified oligonucleotide is a modified nucleoside.

Embodiment 86

The compound of embodiment 85 wherein each modified nucleoside comprises a modified sugar moiety.

Embodiment 87

The compound of embodiment 86, wherein the modified nucleosides of the modified oligonucleotide comprise the same modification as one another.

Embodiment 88

The compound of embodiment 87, wherein the modified nucleosides of the modified oligonucleotide each comprise the same 2′-substituted sugar moiety.

Embodiment 89

The compound of embodiment 88, wherein the 2′-substituted sugar moiety of the modified oligonucleotide is selected from 2′-F, 2′-OMe, and 2′-MOE.

Embodiment 90

The compound of embodiment 89, wherein the 2′-substituted sugar moiety of the modified oligonucleotide is 2′-MOE.

Embodiment 91

The compound of embodiment 87, wherein the modified nucleosides of the modified oligonucleotide each comprise the same bicyclic sugar moiety.

Embodiment 92

The compound of embodiment 91, wherein the bicyclic sugar moiety of the modified oligonucleotide is selected from LNA and cEt.

Embodiment 93

The compound of embodiment 87, wherein the modified nucleosides of the modified oligonucleotide each comprises a sugar surrogate.

Embodiment 94

The compound of embodiment 93, wherein the sugar surrogate of the modified oligonucleotide is a morpholino.

Embodiment 95

The compound of embodiment 93, wherein the sugar surrogate of the modified oligonucleotide is a modified morpholino.

Embodiment 96

The compound of any of embodiments 1-95, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

Embodiment 97

The compound of embodiment 96, wherein each internucleoside linkage is a modified internucleoside linkage.

Embodiment 98

The compound of embodiment 96 or 97, comprising at least one phosphorothioate internucleoside linkage.

Embodiment 99

The compound of embodiment 77, wherein each internucleoside linkage is a modified internucleoside linkage and wherein each internucleoside linkage comprises the same modification.

Embodiment 100

The compound of embodiment 99, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

Embodiment 101

The compound of any of embodiments 1-100 comprising at least one conjugate.

Embodiment 102

The compound of any of embodiments 1-101 consisting of the modified oligonucleotide.

Embodiment 103

The compound of any of embodiments 1-102, wherein the compound modulates splicing of the fibronectin transcript.

Embodiment 104

The compound of any of embodiments 1-103, having a nucleobase sequence comprising any of the sequences as set forth in SEQ ID NOs. 5 to 25 or 30 to 90.

Embodiment 105

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 5.

Embodiment 106

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 9.

Embodiment 107

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 13.

Embodiment 108

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 14.

Embodiment 109

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 15.

Embodiment 110

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 18.

Embodiment 111

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 22.

Embodiment 112

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 66.

Embodiment 113

The compound of any of embodiments 1-103, having a nucleobase sequence comprising the sequence as set forth in SEQ ID NO: 67.

Embodiment 114

The compound of any of embodiments 1-103, wherein the antisense oligonucleotide has a nucleobase sequence comprising CTTCTTCT.

Embodiment 115

The compound of any of embodiments 1-103, wherein the antisense oligonucleotide has a nucleobase sequence comprising GTTCC.

Embodiment 116

The compound of any of embodiments 1-103, wherein the antisense oligonucleotide has a nucleobase sequence comprising GTCCC.

Embodiment 117

A pharmaceutical composition comprising a compound according to any of embodiments 1-116 and a pharmaceutically acceptable carrier or diluent.

Embodiment 118

The pharmaceutical composition of embodiment 117, wherein the pharmaceutically acceptable carrier or diluent is sterile saline.

Embodiment 119

A method of decreasing the amount of EDA+ fibronectin protein in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 120

A method of increasing the amount of EDA− fibronectin protein in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 121

A method of reducing fibrosis, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 122

A method of reversing fibrosis, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 123

A method of reducing changes in cell phenotype due to fibrosis, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 124

A method of reversing changes in cell phenotype due to fibrosis, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 125

The method of embodiments 123-124, wherein the change in cell phenotype due to fibrosis is the modulation of cadherin expression.

Embodiment 126

The method of embodiments 123-124, wherein the change in cell phenotype due to fibrosis is the induction of α Smooth Muscle Actin (αSMA).

Embodiment 127

The method of embodiments 123-124, wherein the change in cell phenotype due to fibrosis is the alteration of cortical f-actin localization.

Embodiment 128

The method of embodiments 123-124, wherein the change in cell phenotype due to fibrosis is the induction of connexin 43 (Cx 43) expression.

Embodiment 129

The method of embodiments 123-124, wherein the change in cell phenotype due to fibrosis is the increased secretion of MMP2 & MMP9.

Embodiment 130

The method of embodiments 123-124, wherein the change in cell phenotype due to fibrosis is the alteration of the amount vimentin or the arrangement of vimentin within a cell.

Embodiment 131

The method of embodiments 123-124, wherein the change in cell phenotype due to fibrosis is the alteration of the amount tight junction protein ZO-1 or the arrangement of tight junction protein ZO-1 within a cell.

Embodiment 132

A method of reducing loss of cell phenotype due to fibrosis, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 133

A method of reversing the loss of cell phenotype due to fibrosis, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 134

A method of increasing the ratio of EDA+/EDA− fibronectin in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 135

A method of decreasing the ratio of EDA+/EDA− fibronectin in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 136

A method of increasing the ratio of EDA−/EDA+ fibronectin in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 137

A method of decreasing the ratio of EDA−/EDA+ fibronectin in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 138

A method of increasing the ratio of EDA+/EDA− fibronectin protein in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 139

A method of decreasing the ratio of EDA+/EDA− fibronectin protein in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 140

A method of increasing the ratio of EDA−/EDA+ fibronectin protein in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 141

A method of decreasing the ratio of EDA−/EDA+ fibronectin protein in a cell, comprising contacting the cell with a compound according to any of embodiments 1-117.

Embodiment 142

The method of any of embodiments 119-142, wherein the cell is in vitro.

Embodiment 143

The method of embodiments 119-142, wherein the cell is in an animal.

Embodiment 144

The method of embodiments 119-142, wherein the animal is a mouse.

Embodiment 145

The method of embodiments 119-142, wherein the animal is a human.

Embodiment 146

The method of any of embodiments 119-145, wherein TGFβ1 is present in the cell.

Embodiment 147

The method of any of embodiments 119-146, wherein the healing and/or restoration functions of the cell are not substantially affected.

Embodiment 148

A pharmaceutical composition comprising a compound according to any of embodiments 1-117 and a pharmaceutically acceptable carrier or diluent.

Embodiment 149

The pharmaceutical composition of embodiment 148, wherein the pharmaceutically acceptable carrier or diluent is sterile saline.

Embodiment 150

A method comprising administering the pharmaceutical composition of embodiments 148 or 149 to an animal.

Embodiment 151

The method of embodiment 150, wherein the animal is a mouse.

Embodiment 152

The method of embodiment 150, wherein the animal is a human.

Embodiment 153

The method of embodiment 150, wherein the administration is by injection.

Embodiment 154

The method of embodiment 150, wherein the administration is systemic.

Embodiment 155

The method of embodiment 150 wherein the administration is local.

Embodiment 156

The method of any of embodiments 150-155, wherein the animal has one or more symptom associated with fibrosis.

Embodiment 157

The method of embodiment 156, wherein the administration results in amelioration of at least one symptom associated with fibrosis.

Embodiment 158

The method of embodiment 156-157, wherein the fibrosis is renal fibrosis.

Embodiment 159

The method of embodiment 156-157, wherein the fibrosis is lung fibrosis.

Embodiment 160

The method of embodiment 156-157, wherein the fibrosis is liver fibrosis.

Embodiment 161

The method of embodiment 156-157, wherein the fibrosis is brain fibrosis.

Embodiment 162

The method of embodiment 156-157, wherein the fibrosis is muscular fibrosis.

Embodiment 163

The method of embodiment 156-157, wherein the fibrosis is cardiovascular fibrosis.

Embodiment 164

The method of embodiment 156-157, wherein the fibrosis is in the bone or the bone marrow.

Embodiment 165

The method of embodiment 156-157, wherein the fibrosis is intestinal fibrosis.

Embodiment 166

The method of embodiment 156-157, wherein the fibrosis is epidural fibrosis.

Embodiment 167

The method of any of embodiments 156-167, wherein the animal is a mouse.

Embodiment 168

The method of any of embodiments 156-167, wherein the animal is a human.

Embodiment 169

Use of the compound of any of embodiments 1 to 117 or the composition of embodiments 148-149 for the preparation of a medicament for use in the treatment of at least one symptom associated with fibrosis.

Embodiment 170

Use of the compound of any of embodiments 1 to 117 or the composition of embodiments 148-149 for the preparation of a medicament for use in the amelioration of one or more symptoms associated with fibrosis.

Embodiment 171

The use of any of embodiment 169-170, wherein the fibrosis is selected from among renal, lung, liver, brain, muscular, cardiovascular, bone or bone marrow, intestinal, and/or epidural fibrosis.

Embodiment 172

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a sugar motif described by Formula I as follows:

[(A)-(B)₂-(A)]_(n)

wherein:

each A is independently a bicyclic nucleoside;

each B is independently a 2′-substituted nucleoside or a 2′-deoxynucleoside; and

n is an integer from 3-6.

Embodiment 173

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a sugar motif described by Formula II as follows:

(A)₂-[(B)₂-(A)]n-(A)

wherein:

each A is independently a bicyclic nucleoside;

each B is independently a 2′-substituted nucleoside or a 2′-deoxynucleoside; and

n is an integer from 3-6.

Embodiment 174

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a sugar motif described by Formula III as follows:

(A)₂-[(B)₂-(A)]_(n)

wherein:

each A is independently a bicyclic nucleoside;

each B is independently a 2′-substituted nucleoside or a 2′-deoxynucleoside; and

n is an integer from 3-6.

Embodiment 175

The compound of any of embodiments 172 to 174, wherein each A comprises a bicyclic nucleoside selected from among LNA and cEt.

Embodiment 176

The compound of any of embodiments 172 to 174, wherein each A comprises a cEt modification.

Embodiment 177

The compound of any of embodiments 172 to 174, wherein each A comprises an LNA modification.

Embodiment 178

The compound of any of embodiments 172 to 177, wherein each B comprises a 2′-substituted nucleoside having a 2′-modification selected from among 2′-OMe, 2′-F, and 2′-MOE.

Embodiment 179

The compound embodiments 178, wherein the 2′-modification is a 2′-MOE modification.

Embodiment 180

The compound of any of embodiments 172 to 179, wherein each B comprises a 2′-deoxynucleoside.

Embodiment 181

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kd₂kd₂kd₂kd₂kd₂k motif, wherein each k comprises a cEt modification and each d comprises a 2′-deoxynucleoside.

Embodiment 182

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kkddkddkddkddkddkk motif, wherein each k comprises a cEt modification and each d comprises a 2′-deoxynucleoside.

Embodiment 183

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kkeekeekeekeekeeke motif, wherein each k comprises a cEt modification and each e comprises a 2′-MOE modification.

Embodiment 184

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kddkddkddkddkddk motif wherein each k comprises a cEt modification and each d comprises a 2′-deoxynucleoside.

Embodiment 185

A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a keekeekeekeekeek motif, wherein each k comprises a cEt modification and each e comprises a 2′-MOE modification.

In certain embodiments, including, but not limited to any of the above numbered embodiments, the fibronectin transcript is in a human. In certain embodiments, including, but not limited to any of the above numbered embodiments, the fibronectin transcript is in a mouse.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a schematic of fibronectin splicing. Exons are represented as boxes and introns are represented as lines. Diagonal lines indicate splicing pathways. As illustrated by the schematic, alternative splicing produces two different mRNA products. Inclusion of the EDA exon results in mRNA containing the EDA exon (EDA+) which results in fibronectin protein having EDA. Alternatively, exclusion of the EDA exon results in mRNA without the EDA exon (EDA−) and results in fibronectin protein without EDA.

DETAILED DESCRIPTION OF THE INVENTION

Unless specific definitions are provided, the nomenclature used in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical synthesis, and chemical analysis. Certain such techniques and procedures may be found for example in “Carbohydrate Modifications in Antisense Research” Edited by Sangvi and Cook, American Chemical Society, Washington D.C., 1994; “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., 21^(st) edition, 2005; and “Antisense Drug Technology, Principles, Strategies, and Applications” Edited by Stanley T. Crooke, CRC Press, Boca Raton, Fla.; and Sambrook et al., “Molecular Cloning, A laboratory Manual,” 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, which are hereby incorporated by reference for any purpose. Where permitted, all patents, applications, published applications and other publications and other data referred to throughout in the disclosure are incorporated by reference herein in their entirety.

Unless otherwise indicated, the following terms have the following meanings:

As used herein, “nucleoside” means a compound comprising a nucleobase moiety and a sugar moiety. Nucleosides include, but are not limited to, naturally occurring nucleosides (as found in DNA and RNA) and modified nucleosides. Nucleosides may be linked to a phosphate moiety.

As used herein, “chemical modification” means a chemical difference in a compound when compared to a naturally occurring counterpart. In reference to an oligonucleotide, chemical modification does not include differences only in nucleobase sequence. Chemical modifications of oligonucleotides include nucleoside modifications (including sugar moiety modifications and nucleobase modifications) and internucleoside linkage modifications.

As used herein, “furanosyl” means a structure comprising a 5-membered ring comprising four carbon atoms and one oxygen atom.

As used herein, “naturally occurring sugar moiety” means a ribofuranosyl as found in naturally occurring RNA or a deoxyribofuranosyl as found in naturally occurring DNA.

As used herein, “sugar moiety” means a naturally occurring sugar moiety or a modified sugar moiety of a nucleoside.

As used herein, “modified sugar moiety” means a substituted sugar moiety, a bicyclic or tricyclic sugar moiety, or a sugar surrogate.

As used herein, “substituted sugar moiety” means a furanosyl comprising at least one substituent group that differs from that of a naturally occurring sugar moiety. Substituted sugar moieties include, but are not limited to furanosyls comprising substituents at the 2′-position, the 3′-position, the 5′-position and/or the 4′-position.

As used herein, “2′-substituted sugar moiety” means a furanosyl comprising a substituent at the 2′-position other than H or OH. Unless otherwise indicated, a 2′-substituted sugar moiety is not a bicyclic sugar moiety (i.e., the 2′-substituent of a 2′-substituted sugar moiety does not form a bridge to another atom of the furanosyl ring.

As used herein, “MOE” means —OCH₂CH₂OCH₃.

As used herein, “bicyclic sugar moiety” means a modified sugar moiety comprising a 4 to 7 membered ring (including but not limited to a furanosyl) comprising a bridge connecting two atoms of the 4 to 7 membered ring to form a second ring, resulting in a bicyclic structure. In certain embodiments, the 4 to 7 membered ring is a sugar ring. In certain embodiments the 4 to 7 membered ring is a furanosyl. In certain such embodiments, the bridge connects the 2′-carbon and the 4′-carbon of the furanosyl.

As used herein the term “sugar surrogate” means a structure that does not comprise a furanosyl and that is capable of replacing the naturally occurring sugar moiety of a nucleoside, such that the resulting nucleoside is capable of (1) incorporation into an oligonucleotide and (2) hybridization to a complementary nucleoside. Such structures include rings comprising a different number of atoms than furanosyl (e.g., 4, 6, or 7-membered rings); replacement of the oxygen of a furanosyl with a non-oxygen atom (e.g., carbon, sulfur, or nitrogen); or both a change in the number of atoms and a replacement of the oxygen. Such structures may also comprise substitutions corresponding to those described for substituted sugar moieties (e.g., 6-membered carbocyclic bicyclic sugar surrogates optionally comprising additional substituents). Sugar surrogates also include more complex sugar replacements (e.g., the non-ring systems of peptide nucleic acid). Sugar surrogates include without limitation morpholino, modified morpholinos, cyclohexenyls and cyclohexitols.

As used herein, “nucleotide” means a nucleoside further comprising a phosphate linking group. As used herein, “linked nucleosides” may or may not be linked by phosphate linkages and thus includes, but is not limited to “linked nucleotides.” As used herein, “linked nucleosides” are nucleosides that are connected in a continuous sequence (i.e. no additional nucleosides are present between those that are linked).

As used herein, “nucleobase” means a group of atoms that can be linked to a sugar moiety to create a nucleoside that is capable of incorporation into an oligonucleotide, and wherein the group of atoms is capable of bonding with a complementary naturally occurring nucleobase of another oligonucleotide or nucleic acid. Nucleobases may be naturally occurring or may be modified.

As used herein, “heterocyclic base” or “heterocyclic nucleobase” means a nucleobase comprising a heterocyclic structure.

As used herein the terms, “unmodified nucleobase” or “naturally occurring nucleobase” means the naturally occurring heterocyclic nucleobases of RNA or DNA: the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) (including 5-methyl C), and uracil (U).

As used herein, “modified nucleobase” means any nucleobase that is not a naturally occurring nucleobase.

As used herein, “modified nucleoside” means a nucleoside comprising at least one chemical modification compared to naturally occurring RNA or DNA nucleosides. Modified nucleosides comprise a modified sugar moiety and/or a modified nucleobase.

As used herein, “bicyclic nucleoside” or “BNA” means a nucleoside comprising a bicyclic sugar moiety.

As used herein, “constrained ethyl nucleoside” or “cEt” means a nucleoside comprising a bicyclic sugar moiety comprising a 4′-CH(CH₃)—O-2′ bridge.

As used herein, “locked nucleic acid nucleoside” or “LNA” means a nucleoside comprising a bicyclic sugar moiety comprising a 4′-CH₂—O-2′ bridge.

As used herein, “2′-substituted nucleoside” means a nucleoside comprising a substituent at the 2′-position other than H or OH. Unless otherwise indicated, a 2′-substituted nucleoside is not a bicyclic nucleoside.

As used herein, “2′-deoxynucleoside” means a nucleoside comprising 2′-H furanosyl sugar moiety, as found in naturally occurring deoxyribonucleosides (DNA). In certain embodiments, a 2′-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (e.g., uracil).

As used herein, “oligonucleotide” means a compound comprising a plurality of linked nucleosides. In certain embodiments, an oligonucleotide comprises one or more unmodified ribonucleosides (RNA) and/or unmodified deoxyribonucleosides (DNA) and/or one or more modified nucleosides.

As used herein “oligonucleoside” means an oligonucleotide in which none of the internucleoside linkages contains a phosphorus atom. As used herein, oligonucleotides include oligonucleosides.

As used herein, “modified oligonucleotide” means an oligonucleotide comprising at least one modified nucleoside and/or at least one modified internucleoside linkage.

As used herein “internucleoside linkage” means a covalent linkage between adjacent nucleosides in an oligonucleotide.

As used herein “naturally occurring internucleoside linkage” means a 3′ to 5′ phosphodiester linkage.

As used herein, “modified internucleoside linkage” means any internucleoside linkage other than a naturally occurring internucleoside linkage.

As used herein, “oligomeric compound” means a polymeric structure comprising two or more sub-structures. In certain embodiments, an oligomeric compound comprises an oligonucleotide. In certain embodiments, an oligomeric compound comprises one or more conjugate groups and/or terminal groups. In certain embodiments, an oligomeric compound consists of an oligonucleotide.

As used herein, “terminal group” means one or more atom attached to either, or both, the 3′ end or the 5′ end of an oligonucleotide. In certain embodiments a terminal group is a conjugate group. In certain embodiments, a terminal group comprises one or more terminal group nucleosides.

As used herein, “conjugate” means an atom or group of atoms bound to an oligonucleotide or oligomeric compound. In general, conjugate groups modify one or more properties of the compound to which they are attached, including, but not limited to pharmacodynamic, pharmacokinetic, binding, absorption, cellular distribution, cellular uptake, charge and/or clearance properties.

As used herein, “conjugate linking group” means any atom or group of atoms used to attach a conjugate to an oligonucleotide or oligomeric compound.

As used herein, “antisense compound” means a compound comprising or consisting of an oligonucleotide at least a portion of which is complementary to a target nucleic acid to which it is capable of hybridizing, resulting in at least one antisense activity.

As used herein, “antisense activity” means any detectable and/or measurable change attributable to the hybridization of an antisense compound to its target nucleic acid.

As used herein, “detecting” or “measuring” means that a test or assay for detecting or measuring is performed. Such detection and/or measuring may result in a value of zero. Thus, if a test for detection or measuring results in a finding of no activity (activity of zero), the step of detecting or measuring the activity has nevertheless been performed.

As used herein, “detectable and/or measurable activity” means a statistically significant activity that is not zero.

As used herein, “essentially unchanged” means little or no change in a particular parameter, particularly relative to another parameter which changes much more. In certain embodiments, a parameter is essentially unchanged when it changes less than 5%. In certain embodiments, a parameter is essentially unchanged if it changes less than two-fold while another parameter changes at least ten-fold. For example, in certain embodiments, an antisense activity is a change in the amount of a target nucleic acid. In certain such embodiments, the amount of a non-target nucleic acid is essentially unchanged if it changes much less than the target nucleic acid does, but the change need not be zero.

As used herein, “expression” means the process by which a gene ultimately results in a protein. Expression includes, but is not limited to, transcription, post-transcriptional modification (e.g., splicing, polyadenlyation, addition of 5′-cap), and translation.

As used herein, “target nucleic acid” means a nucleic acid molecule to which an antisense compound hybridizes.

As used herein, “mRNA” means an RNA molecule that encodes a protein.

As used herein, “pre-mRNA” means an RNA transcript that has not been fully processed into mRNA. Pre-RNA includes one or more intron.

As used herein, “transcript” means an RNA molecule transcribed from DNA. Transcripts include, but are not limited to mRNA, pre-mRNA, and partially processed RNA.

As used herein, “fibronectin transcript” means a transcript transcribed from a fibronectin gene. In certain embodiments, a fibronectin transcript comprises SEQ ID NO: 1: the complement of GENBANK Accession No. NT_005403.14 truncated from nucleotides 66434501 to 66510708.

As used herein, “fibronectin gene” means a gene that encodes a fibronectin protein and any fibronectin protein isoforms. In certain embodiments, a fibronectin gene is represented by GENBANK Accession No. NT_005403.14 truncated from nucleotides 66434501 to 66510708, or a variant thereof. In certain embodiments, a fibronectin gene is at least 95% identical to GENBANK Accession No. NT_005403.14 truncated from nucleotides 66434501 to 66510708. In certain embodiments, a fibronectin gene is at least 90% identical to GENBANK Accession No. NT_005403.14 truncated from nucleotides 66434501 to 66510708.

As used herein, “EDA− fibronectin protein” means a fibronectin protein isoform that does not contain extra type III domain A.

As used herein, “EDA+ fibronectin protein” means a fibronectin protein isoform that contains extra type III domain A.

As used herein, “EDA− fibronectin mRNA” means a fibronectin transcript that does not contain the extra type III domain A exon.

As used herein, “EDA+ fibronectin mRNA” means a fibronectin transcript that contains the extra type III domain A exon.

As used herein, “targeting” or “targeted to” means the association of an antisense compound to a particular target nucleic acid molecule or a particular region of a target nucleic acid molecule. An antisense compound targets a target nucleic acid if it is sufficiently complementary to the target nucleic acid to allow hybridization under physiological conditions.

As used herein, “nucleobase complementarity” or “complementarity” when in reference to nucleobases means a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, complementary nucleobase means a nucleobase of an antisense compound that is capable of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be complementary at that nucleobase pair. Nucleobases comprising certain modifications may maintain the ability to pair with a counterpart nucleobase and thus, are still capable of nucleobase complementarity.

As used herein, “non-complementary” in reference to nucleobases means a pair of nucleobases that do not form hydrogen bonds with one another.

As used herein, “complementary” in reference to oligomeric compounds (e.g., linked nucleosides, oligonucleotides, or nucleic acids) means the capacity of such oligomeric compounds or regions thereof to hybridize to another oligomeric compound or region thereof through nucleobase complementarity under stringent conditions. Complementary oligomeric compounds need not have nucleobase complementarity at each nucleoside. Rather, some mismatches are tolerated. In certain embodiments, complementary oligomeric compounds or regions are complementary at 70% of the nucleobases (70% complementary). In certain embodiments, complementary oligomeric compounds or regions are 80% complementary. In certain embodiments, complementary oligomeric compounds or regions are 90% complementary. In certain embodiments, complementary oligomeric compounds or regions are 95% complementary. In certain embodiments, complementary oligomeric compounds or regions are 100% complementary.

As used herein, “hybridization” means the pairing of complementary oligomeric compounds (e.g., an antisense compound and its target nucleic acid). While not limited to a particular mechanism, the most common mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.

As used herein, “specifically hybridizes” means the ability of an oligomeric compound to hybridize to one nucleic acid site with greater affinity than it hybridizes to another nucleic acid site. In certain embodiments, an antisense oligonucleotide specifically hybridizes to more than one target site.

As used herein, “percent complementarity” means the percentage of nucleobases of an oligomeric compound that are complementary to an equal-length portion of a target nucleic acid. Percent complementarity is calculated by dividing the number of nucleobases of the oligomeric compound that are complementary to nucleobases at corresponding positions in the target nucleic acid by the total length of the oligomeric compound.

As used herein, “percent identity” means the number of nucleobases in a first nucleic acid that are the same type (independent of chemical modification) as nucleobases at corresponding positions in a second nucleic acid, divided by the total number of nucleobases in the first nucleic acid.

As used herein, “modulation” means a change of amount or quality of a molecule, function, or activity when compared to the amount or quality of a molecule, function, or activity prior to modulation. For example, modulation includes the change, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in gene expression. As a further example, modulation of expression can include a change in splice site selection of pre-mRNA processing, resulting in a change in the absolute or relative amount of a particular splice-variant compared to the amount in the absence of modulation.

As used herein, “motif” means a pattern of chemical modifications in an oligomeric compound or a region thereof. Motifs may be defined by modifications at certain nucleosides and/or at certain linking groups of an oligomeric compound.

As used herein, “nucleoside motif” means a pattern of nucleoside modifications in an oligomeric compound or a region thereof. The linkages of such an oligomeric compound may be modified or unmodified. Unless otherwise indicated, motifs herein describing only nucleosides are intended to be nucleoside motifs. Thus, in such instances, the linkages are not limited.

As used herein, “sugar motif” means a pattern of sugar modifications in an oligomeric compound or a region thereof.

As used herein, “linkage motif” means a pattern of linkage modifications in an oligomeric compound or region thereof. The nucleosides of such an oligomeric compound may be modified or unmodified. Unless otherwise indicated, motifs herein describing only linkages are intended to be linkage motifs. Thus, in such instances, the nucleosides are not limited.

As used herein, “nucleobase modification motif” means a pattern of modifications to nucleobases along an oligonucleotide. Unless otherwise indicated, a nucleobase modification motif is independent of the nucleobase sequence.

As used herein, “sequence motif” means a pattern of nucleobases arranged along an oligonucleotide or portion thereof. Unless otherwise indicated, a sequence motif is independent of chemical modifications and thus may have any combination of chemical modifications, including no chemical modifications.

As used herein, “type of modification” in reference to a nucleoside or a nucleoside of a “type” means the chemical modification of a nucleoside and includes modified and unmodified nucleosides. Accordingly, unless otherwise indicated, a “nucleoside having a modification of a first type” may be an unmodified nucleoside.

As used herein, “differently modified” mean chemical modifications or chemical substituents that are different from one another, including absence of modifications. Thus, for example, a MOE nucleoside and an unmodified DNA nucleoside are “differently modified,” even though the DNA nucleoside is unmodified. Likewise, DNA and RNA are “differently modified,” even though both are naturally-occurring unmodified nucleosides. Nucleosides that are the same but for comprising different nucleobases are not differently modified. For example, a nucleoside comprising a 2′-OMe modified sugar and an unmodified adenine nucleobase and a nucleoside comprising a 2′-OMe modified sugar and an unmodified thymine nucleobase are not differently modified.

As used herein, “the same type of modifications” refers to modifications that are the same as one another, including absence of modifications. Thus, for example, two unmodified DNA nucleoside have “the same type of modification,” even though the DNA nucleoside is unmodified. Such nucleosides having the same type modification may comprise different nucleobases.

As used herein, “pharmaceutically acceptable carrier or diluent” means any substance suitable for use in administering to an animal. In certain embodiments, a pharmaceutically acceptable carrier or diluent is sterile saline. In certain embodiments, such sterile saline is pharmaceutical grade saline.

As used herein, “substituent” and “substituent group,” means an atom or group that replaces the atom or group of a named parent compound. For example a substituent of a modified nucleoside is any atom or group that differs from the atom or group found in a naturally occurring nucleoside (e.g., a modified 2′-substituent is any atom or group at the 2′-position of a nucleoside other than H or OH). Substituent groups can be protected or unprotected. In certain embodiments, compounds of the present invention have substituents at one or at more than one position of the parent compound. Substituents may also be further substituted with other substituent groups and may be attached directly or via a linking group such as an alkyl or hydrocarbyl group to a parent compound.

Likewise, as used herein, “substituent” in reference to a chemical functional group means an atom or group of atoms differs from the atom or a group of atoms normally present in the named functional group. In certain embodiments, a substituent replaces a hydrogen atom of the functional group (e.g., in certain embodiments, the substituent of a substituted methyl group is an atom or group other than hydrogen which replaces one of the hydrogen atoms of an unsubstituted methyl group). Unless otherwise indicated, groups amenable for use as substituents include without limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl (—C(O)R_(aa)), carboxyl (—C(O)O—R_(aa)), aliphatic groups, alicyclic groups, alkoxy, substituted oxy (—O—R_(aa)), aryl, aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino (—N(R_(bb))(R_(cc))), imino(═NR_(bb)), amido (—C(O)N(R_(bb))(R_(cc)) or —N(R_(bb))C(O)R_(aa)), azido (—N₃), nitro (—NO₂), cyano (—CN), carbamido (—OC(O)N(R_(bb))(R_(cc)) or —N(R_(bb))C(O)OR_(aa)), ureido (—N(R_(bb))C(O)N(R_(bb))(R_(cc))), thioureido (—N(R_(bb))C(S)N(R_(bb))—(R_(cc))), guanidinyl (—N(R_(bb))C(═NR_(bb))N(R_(bb))(R_(cc))), amidinyl (—C(═NR_(bb))N(R_(bb))(R_(cc)) or —N(R_(bb))C(═NR_(bb))(R_(aa))), thiol (—SR_(bb)), sulfinyl (—S(O)R_(bb)), sulfonyl (—S(O)₂R_(bb)) and sulfonamidyl (—S(O)₂N(R_(bb))(R_(cc)) or —N(R_(bb))S—(O)₂R_(bb)). Wherein each R_(aa), R_(bb) and R_(cc) is, independently, H, an optionally linked chemical functional group or a further substituent group with a preferred list including without limitation, alkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic, heterocyclic and heteroarylalkyl. Selected substituents within the compounds described herein are present to a recursive degree.

As used herein, “alkyl,” as used herein, means a saturated straight or branched hydrocarbon radical containing up to twenty four carbon atoms. Examples of alkyl groups include without limitation, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like. Alkyl groups typically include from 1 to about 24 carbon atoms, more typically from 1 to about 12 carbon atoms (C₁-C₁₂ alkyl) with from 1 to about 6 carbon atoms being more preferred.

As used herein, “alkenyl,” means a straight or branched hydrocarbon chain radical containing up to twenty four carbon atoms and having at least one carbon-carbon double bond. Examples of alkenyl groups include without limitation, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, dienes such as 1,3-butadiene and the like. Alkenyl groups typically include from 2 to about 24 carbon atoms, more typically from 2 to about 12 carbon atoms with from 2 to about 6 carbon atoms being more preferred. Alkenyl groups as used herein may optionally include one or more further substituent groups.

As used herein, “alkynyl,” means a straight or branched hydrocarbon radical containing up to twenty four carbon atoms and having at least one carbon-carbon triple bond. Examples of alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl, and the like. Alkynyl groups typically include from 2 to about 24 carbon atoms, more typically from 2 to about 12 carbon atoms with from 2 to about 6 carbon atoms being more preferred. Alkynyl groups as used herein may optionally include one or more further substituent groups.

As used herein, “acyl,” means a radical formed by removal of a hydroxyl group from an organic acid and has the general Formula —C(O)—X where X is typically aliphatic, alicyclic or aromatic. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates, aliphatic phosphates and the like. Acyl groups as used herein may optionally include further substituent groups.

As used herein, “alicyclic” means a cyclic ring system wherein the ring is aliphatic. The ring system can comprise one or more rings wherein at least one ring is aliphatic. Preferred alicyclics include rings having from about 5 to about 9 carbon atoms in the ring. Alicyclic as used herein may optionally include further substituent groups.

As used herein, “aliphatic” means a straight or branched hydrocarbon radical containing up to twenty four carbon atoms wherein the saturation between any two carbon atoms is a single, double or triple bond. An aliphatic group preferably contains from 1 to about 24 carbon atoms, more typically from 1 to about 12 carbon atoms with from 1 to about 6 carbon atoms being more preferred. The straight or branched chain of an aliphatic group may be interrupted with one or more heteroatoms that include nitrogen, oxygen, sulfur and phosphorus. Such aliphatic groups interrupted by heteroatoms include without limitation, polyalkoxys, such as polyalkylene glycols, polyamines, and polyimines. Aliphatic groups as used herein may optionally include further substituent groups.

As used herein, “alkoxy” means a radical formed between an alkyl group and an oxygen atom wherein the oxygen atom is used to attach the alkoxy group to a parent molecule. Examples of alkoxy groups include without limitation, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groups as used herein may optionally include further substituent groups.

As used herein, “aminoalkyl” means an amino substituted C₁-C₁₂ alkyl radical. The alkyl portion of the radical forms a covalent bond with a parent molecule. The amino group can be located at any position and the aminoalkyl group can be substituted with a further substituent group at the alkyl and/or amino portions.

As used herein, “aralkyl” and “arylalkyl” mean an aromatic group that is covalently linked to a C₁-C₁₂ alkyl radical. The alkyl radical portion of the resulting aralkyl (or arylalkyl) group forms a covalent bond with a parent molecule. Examples include without limitation, benzyl, phenethyl and the like. Aralkyl groups as used herein may optionally include further substituent groups attached to the alkyl, the aryl or both groups that form the radical group.

As used herein, “aryl” and “aromatic” mean a mono- or polycyclic carbocyclic ring system radicals having one or more aromatic rings. Examples of aryl groups include without limitation, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like. Preferred aryl ring systems have from about 5 to about 20 carbon atoms in one or more rings. Aryl groups as used herein may optionally include further substituent groups.

As used herein, “halo” and “halogen,” mean an atom selected from fluorine, chlorine, bromine and iodine.

As used herein, “heteroaryl,” and “heteroaromatic,” mean a radical comprising a mono- or polycyclic aromatic ring, ring system or fused ring system wherein at least one of the rings is aromatic and includes one or more heteroatoms. Heteroaryl is also meant to include fused ring systems including systems where one or more of the fused rings contain no heteroatoms. Heteroaryl groups typically include one ring atom selected from sulfur, nitrogen or oxygen. Examples of heteroaryl groups include without limitation, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl and the like. Heteroaryl radicals can be attached to a parent molecule directly or through a linking moiety such as an aliphatic group or hetero atom. Heteroaryl groups as used herein may optionally include further substituent groups.

Oligomeric Compounds

In certain embodiments, the present invention provides oligomeric compounds. In certain embodiments, such oligomeric compounds comprise oligonucleotides optionally comprising one or more conjugate and/or terminal groups. In certain embodiments, an oligomeric compound consists of an oligonucleotide. In certain embodiments, oligonucleotides comprise one or more chemical modifications. Such chemical modifications include modifications one or more nucleoside (including modifications to the sugar moiety and/or the nucleobase) and/or modifications to one or more internucleoside linkage.

Certain Sugar Moieties

In certain embodiments, oligomeric compounds of the invention comprise one or more modified nucleosides comprising a modified sugar moiety. Such oligomeric compounds comprising one or more sugar-modified nucleosides may have desirable properties, such as enhanced nuclease stability or increased binding affinity with a target nucleic acid relative to oligomeric compounds comprising only nucleosides comprising naturally occurring sugar moieties. In certain embodiments, modified sugar moieties are substituted sugar moieties. In certain embodiments, modified sugar moieties are bicyclic or tricyclic sugar moieties. In certain embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of substituted sugar moieties.

In certain embodiments, modified sugar moieties are substituted sugar moieties comprising one or more substituent, including but not limited to substituents at the 2′ and/or 5′ positions. Examples of sugar substituents suitable for the 2′-position, include, but are not limited to: 2′-F, 2′-OCH₃ (“OMe” or “O-methyl”), and 2′-O(CH₂)₂OCH₃ (“MOE”). In certain embodiments, sugar substituents at the 2′ position is selected from allyl, amino, azido, thio, O-allyl, O—C₁-C₁₀ alkyl, O—C₁-C₁₀ substituted alkyl; I—C₁-C₁₀ alkoxy; O—C₁-C₁₀ substituted alkoxy, OCF₃, O(CH₂)₂SCH₃, O(CH₂)₂—O—N(Rm)(Rn), and O—CH₂—C(═O)—N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl. Examples of sugar substituents at the 5′-position, include, but are not limited to: 5′-methyl (R or S); 5′-vinyl, and 5′-methoxy. In certain embodiments, substituted sugars comprise more than one non-bridging sugar substituent, for example, 2′-F-5′-methyl sugar moieties (see, e.g., PCT International Application WO 2008/101157, for additional 5′, 2′-bis substituted sugar moieties and nucleosides).

Nucleosides comprising 2′-substituted sugar moieties are referred to as 2′-substituted nucleosides. In certain embodiments, a 2′-substituted nucleoside comprises a 2′-substituent group selected from halo, allyl, amino, azido, O—C₁-C₁₀ alkoxy; O—C₁-C₁₀ substituted alkoxy, SH, CN, OCN, CF₃, OCF₃, O-alkyl, S-alkyl, N(R_(m))-alkyl; O-alkenyl, S-alkenyl, or N(R_(m))-alkenyl; O-alkynyl, S-alkynyl, N(R_(m))-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is, independently, H, an amino protecting group or substituted or unsubstituted C₁-C₁₀ alkyl. These 2′-substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.

In certain embodiments, a 2′-substituted nucleoside comprises a 2′-substituent group selected from F, NH₂, N₃, OCF₃, O—CH₃, O(CH₂)₃NH₂, CH₂—CH═CH₂, O—CH₂—CH═CH₂, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)), O(CH₂)₂O(CH₂)₂N(CH₃)₂, and N-substituted acetamide (O—CH₂—C(═O)—N(R_(m))(R_(n)) where each R_(m) and R_(n) is, independently, H, an amino protecting group or substituted or unsubstituted C₁-C₁₀ alkyl.

In certain embodiments, a 2′-substituted nucleoside comprises a sugar moiety comprising a 2′-substituent group selected from F, OCF₃, O—CH₃, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(CH₃)₂, —O(CH₂)₂O(CH₂)₂N(CH₃)₂, and O—CH₂—C(═O)—N(H)CH₃.

In certain embodiments, a 2′-substituted nucleoside comprises a sugar moiety comprising a 2′-substituent group selected from F, O—CH₃, and OCH₂CH₂OCH₃.

Certain modified sugar moieties comprise a bridging sugar substituent that forms a second ring resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety comprises a bridge between the 4′ and the 2′ furanose ring atoms. Examples of such 4′ to 2′ sugar substituents, include, but are not limited to: —[C(R_(a))(R_(b))]_(n)—, —[C(R_(a))(R_(b))]_(n)—O—, —C(R_(a)R_(b))—N(R)—O— or, —C(R_(a)R_(b))—O—N(R)—; 4′- CH₂-2′, 4′-(CH₂)₂-2′, 4′-(CH₂)₃-2′; 4′-(CH₂)—O-2′ (LNA); 4′-(CH₂)—S-2′; 4′-(CH₂)₂—O-2′ (ENA); 4′-CH(CH₃)—O-2′ (cEt) and 4′-CH(CH₂OCH₃)—O-2′, and analogs thereof (see, e.g., U.S. Pat. No. 7,399,845, issued on Jul. 15, 2008); 4′-C(CH₃)(CH₃)—O-2′ and analogs thereof, (see, e.g., WO2009/006478, published Jan. 8, 2009); 4′-CH₂—N(OCH₃)-2′ and analogs thereof (see, e.g., WO2008/150729, published Dec. 11, 2008); 4′-CH₂—O—N(CH₃)-2′ (see, e.g., US2004/0171570, published Sep. 2, 2004); 4′-CH₂—O—N(R)-2′, and 4′-CH₂—N(R)-0-2′-, wherein each R is, independently, H, a protecting group, or C₁-C₁₂ alkyl; 4′-CH₂—N(R)—O-2′, wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see, U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008); 4′-CH₂—C(H)(CH₃)-2′ (see, e.g., Chattopadhyaya, et al., J. Org. Chem., 2009, 74, 118-134); and 4′-CH₂—C(═CH₂)-2′ and analogs thereof (see, published PCT International Application WO 2008/154401, published on Dec. 8, 2008).

In certain embodiments, such 4′ to 2′ bridges independently comprise from 1 to 4 linked groups independently selected from —[C(R_(a))(R_(b))]_(n)—, —C(R_(a))═C(R_(b))—, —C(R_(a))═N—, —C(═NR_(a))—, —C(═O)—, —C(═S)—, —O—, —Si(R_(a))₂—, —S(═O)_(x)—, and —N(R_(a))—;

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_(a) and R_(b) is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O)₂-J₁), or sulfoxyl (S(═O)-J₁); and each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl (C(═O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl, or a protecting group.

Nucleosides comprising bicyclic sugar moieties are referred to as bicyclic nucleosides or BNAs. Bicyclic nucleosides include, but are not limited to, (A) α-L-Methyleneoxy (4′-CH₂—O-2′) BNA, (B) β-D-Methyleneoxy (4′-CH₂—O-2′) BNA (also referred to as locked nucleic acid or LNA), (C) Ethyleneoxy (4′-(CH₂)₂—O-2′) BNA, (D) Aminooxy (4′-CH₂—O—N(R)-2′) BNA, (E) Oxyamino (4′-CH₂—N(R)—O-2′) BNA, (F) Methyl(methyleneoxy) (4′-CH(CH₃)—O-2′) BNA (also referred to as constrained ethyl or cEt), (G) methylene-thio (4′-CH₂—S-2′) BNA, (H) methylene-amino (4′-CH₂—N(R)-2′) BNA, (I) methyl carbocyclic (4′-CH₂—CH(CH₃)-2′) BNA, and (J) propylene carbocyclic (4′-(CH₂)₃-2′) BNA as depicted below.

wherein Bx is a nucleobase moiety and R is, independently, H, a protecting group, or C₁-C₁₂ alkyl.

Additional bicyclic sugar moieties are known in the art, for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J Am. Chem. Soc., 129(26) 8362-8379 (Jul. 4, 2007); Elayadi et al., Curr. Opinion Invens. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos. 7,053,207, 6,268,490, 6,770,748, 6,794,499, 7,034,133, 6,525,191, 6,670,461, and 7,399,845; WO 2004/106356, WO 1994/14226, WO 2005/021570, and WO 2007/134181; U.S. Patent Publication Nos. US2004/0171570, US2007/0287831, and US2008/0039618; U.S. patent Ser. Nos. 12/129,154, 60/989,574, 61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and 61/099,844; and PCT International Applications Nos. PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922.

In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration. For example, a nucleoside comprising a 4′-2′ methylene-oxy bridge, may be in the α-L configuration or in the β-D configuration. Previously, α-L-methyleneoxy (4′-CH₂—O-2′) bicyclic nucleosides have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372).

In certain embodiments, substituted sugar moieties comprise one or more non-bridging sugar substituent and one or more bridging sugar substituent (e.g., 5′-substituted and 4′-2′ bridged sugars). (see, PCT International Application WO 2007/134181, published on Nov. 22, 2007, wherein LNA is substituted with, for example, a 5′-methyl or a 5′-vinyl group).

In certain embodiments, modified sugar moieties are sugar surrogates. In certain such embodiments, the oxygen atom of the naturally occurring sugar is substituted, e.g., with a sulfur, carbon or nitrogen atom. In certain such embodiments, such modified sugar moiety also comprises bridging and/or non-bridging substituents as described above. For example, certain sugar surrogates comprise a 4′-sulfur atom and a substitution at the 2′-position (see, e.g., published U.S. Patent Application US2005/0130923, published on Jun. 16, 2005) and/or the 5′ position. By way of additional example, carbocyclic bicyclic nucleosides having a 4′-2′ bridge have been described (see, e.g., Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek et al., J. Org. Chem., 2006, 71, 7731-7740).

In certain embodiments, sugar surrogates comprise rings having other than 5-atoms. For example, in certain embodiments, a sugar surrogate comprises a six-membered tetrahydropyran. Such tetrahydropyrans may be further modified or substituted. Nucleosides comprising such modified tetrahydropyrans include, but are not limited to, hexitol nucleic acid (HNA), annitol nucleic acid (ANA), mannitol nucleic acid (MNA) (see Leumann, C J. Bioorg. & Med. Chem. (2002) 10:841-854), fluoro HNA (F-HNA), and those compounds having Formula VII:

wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula VII:

Bx is a nucleobase moiety;

T₃ and T₄ are each, independently, an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound or one of T₃ and T₄ is an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound and the other of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugate group, or a 5′ or 3′-terminal group;

q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; and each of R₁ and R₂ is independently selected from among: hydrogen, halogen, substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(═X)J₁, OC(═X)NJ₁J₂, NJ₃C(═X)NJ₁J₂, and CN, wherein X is O, S or NJ₁, and each J₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, the modified THP nucleosides of Formula VII are provided wherein q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is other than H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is methyl. In certain embodiments, THP nucleosides of Formula VII are provided wherein one of R₁ and R₂ is F. In certain embodiments, R₁ is fluoro and R₂ is H, R₁ is methoxy and R₂ is H, and R₁ is methoxyethoxy and R₂ is H.

Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used to modify nucleosides (see, e.g., review article: Leumann, J. C, Bioorganic & Medicinal Chemistry, 2002, 10, 841-854).

In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example nucleosides comprising morpholino sugar moieties and their use in oligomeric compounds has been reported (see for example: Braasch et al., Biochemistry, 2002, 41, 4503-4510; and U.S. Pat. Nos. 5,698,685; 5,166,315; 5,185,444; and 5,034,506). As used here, the term “morpholino” means a sugar surrogate having the following structure:

In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as “modified morpholinos.”

Combinations of modifications are also provided without limitation, such as 2′-F-5′-methyl substituted nucleosides (see PCT International Application WO 2008/101157 Published on Aug. 21, 2008 for other disclosed 5′, 2′-bis substituted nucleosides) and replacement of the ribosyl ring oxygen atom with S and further substitution at the 2′-position (see published U.S. Patent Application US2005-0130923, published on Jun. 16, 2005) or alternatively 5′-substitution of a bicyclic nucleic acid (see PCT International Application WO 2007/134181, published on Nov. 22, 2007 wherein a 4′-CH₂—O-2′ bicyclic nucleoside is further substituted at the 5′ position with a 5′-methyl or a 5′-vinyl group). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (see, e.g., Srivastava et al., J Am. Chem. Soc. 2007, 129(26), 8362-8379).

Certain Nucleobases

In certain embodiments, nucleosides of the present invention comprise one or more unmodified nucleobases. In certain embodiments, nucleosides of the present invention comprise one or more modified nucleobases.

In certain embodiments, modified nucleobases are selected from: universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil; 5-propynylcytosine; 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C≡C≡CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and 3-deazaadenine, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine([5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, U.S. Pat. Nos. 3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and 6,005,096, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Certain Internucleoside Linkages

In certain embodiments, the present invention provides oligomeric compounds comprising linked nucleosides. In such embodiments, nucleosides may be linked together using any internucleoside linkage. The two main classes of internucleoside linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters (P═O), phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates (P═S). Representative non-phosphorus containing internucleoside linking groups include, but are not limited to, methylenemethylimino (—CH₂—N(CH₃)—O—CH₂—), thiodiester (—O—C(O)—S—), thionocarbamate (—O—C(O)(NH)—S—); siloxane (—O—Si(H)₂—O—); and N,N′-dimethylhydrazine (—CH₂—N(CH₃)—N(CH₃)—). Modified linkages, compared to natural phosphodiester linkages, can be used to alter, typically increase, nuclease resistance of the oligomeric compound. In certain embodiments, internucleoside linkages having a chiral atom can be prepared as a racemic mixture, or as separate enantiomers. Representative chiral linkages include, but are not limited to, alkylphosphonates and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing internucleoside linkages are well known to those skilled in the art.

The oligonucleotides described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), α or β such as for sugar anomers, or as (D) or (L) such as for amino acids etc. Included in the antisense compounds provided herein are all such possible isomers, as well as their racemic and optically pure forms.

Neutral internucleoside linkages include without limitation, phosphotriesters, methylphosphonates, MMI (3′-CH₂—N(CH₃)—O-5′), amide-3 (3′-CH₂—C(═O)—N(H)-5′), amide-4 (3′-CH₂—N(H)—C(═O)-5′), formacetal (3′-O—CH₂—O-5′), and thioformacetal (3′-S—CH₂—O-5′). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See for example: Carbohydrate Modifications in Antisense Research; Y. S. Sanghvi and P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, O, S and CH₂ component parts.

Certain Motifs

In certain embodiments, the present invention provides oligomeric compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides comprise one or more chemical modification. In certain embodiments, chemically modified oligonucleotides comprise one or more modified nucleosides. In certain embodiments, chemically modified oligonucleotides comprise one or more modified nucleosides comprising modified sugars. In certain embodiments, chemically modified oligonucleotides comprise one or more modified nucleosides comprising one or more modified nucleobases. In certain embodiments, chemically modified oligonucleotides comprise one or more modified internucleoside linkages. In certain embodiments, the chemically modifications (sugar modifications, nucleobase modifications, and/or linkage modifications) define a pattern or motif. In certain embodiments, the patterns of chemical modifications of sugar moieties, internucleoside linkages, and nucleobases are each independent of one another. Thus, an oligonucleotide may be described by its sugar modification motif, internucleoside linkage motif and/or nucleobase modification motif (as used herein, nucleobase modification motif describes the chemical modifications to the nucleobases independent of the sequence of nucleobases).

Certain Sugar Motifs

In certain embodiments, oligonucleotides comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif. Such motifs may include any of the sugar modifications discussed herein and/or other known sugar modifications.

In certain embodiments, the oligonucleotides comprise or consist of a region having a gapmer sugar modification motif, which comprises two external regions or “wings” and an internal region or “gap.” The three regions of a gapmer motif (the 5′-wing, the gap, and the 3′-wing) form a contiguous sequence of nucleosides wherein at least some of the sugar moieties of the nucleosides of each of the wings differ from at least some of the sugar moieties of the nucleosides of the gap. Specifically, at least the sugar moieties of the nucleosides of each wing that are closest to the gap (the 3′-most nucleoside of the 5′-wing and the 5′-most nucleoside of the 3′-wing) differ from the sugar moiety of the neighboring gap nucleosides, thus defining the boundary between the wings and the gap. In certain embodiments, the sugar moieties within the gap are the same as one another. In certain embodiments, the gap includes one or more nucleoside having a sugar moiety that differs from the sugar moiety of one or more other nucleosides of the gap. In certain embodiments, the sugar modification motifs of the two wings are the same as one another (symmetric gapmer). In certain embodiments, the sugar modification motifs of the 5′-wing differs from the sugar modification motif of the 3′-wing (asymmetric gapmer). In certain embodiments, oligonucleotides comprise 2′-MOE modified nucleosides in the wings and 2′-F modified nucleosides in the gap.

In certain embodiments, oligonucleotides are fully modified. In certain such embodiments, oligonucleotides are uniformly modified. In certain embodiments, oligonucleotides are uniform 2′-MOE. In certain embodiments, oligonucleotides are uniform 2′-F. In certain embodiments, oligonucleotides are uniform morpholino. In certain embodiments, oligonucleotides are uniform BNA. In certain embodiments, oligonucleotides are uniform LNA. In certain embodiments, oligonucleotides are uniform cEt.

In certain embodiments, oligonucleotides comprise a uniformly modified region and additional nucleosides that are unmodified or differently modified. In certain embodiments, the uniformly modified region is at least 5, 10, 15, or 20 nucleosides in length. In certain embodiments, the uniform region is a 2′-MOE region. In certain embodiments, the uniform region is a 2′-F region. In certain embodiments, the uniform region is a morpholino region. In certain embodiments, the uniform region is a BNA region. In certain embodiments, the uniform region is a LNA region. In certain embodiments, the uniform region is a cEt region.

In certain embodiments, the oligonucleotide does not comprise more than 4 contiguous unmodified 2′-deoxynucleosides. In certain circumstances, antisense oligonucleotides comprising more than 4 contiguous 2′-deoxynucleosides activate RNase H, resulting in cleavage of the target RNA. In certain embodiments, such cleavage is avoided by not having more than 4 contiguous 2′-deoxynucleosides, for example, where alteration of splicing and not cleavage of a target RNA is desired.

Certain Splicing Motifs

In certain embodiments, oligonucleotides have a certain modification pattern and/or motif designed to alter the splicing of certain nucleic acid transcripts. In certain embodiments, oligonucleotides have a certain modification pattern and/or motif designed to alter the splicing of certain pre-mRNA transcripts. In certain embodiments, oligonucleotides have a certain modification pattern and/or motif designed in such a fashion that the oligonucleotide will not recruit RNase H once bound to a target nucleic acid transcript. For example, in certain such embodiments, an oligonucleotide may have one or more sugar modifications placed throughout the oligonucleotide so as to have no segment comprising more than 4 contiguous 2′-deoxynucleosides. In certain such embodiments, an oligonucleotide may have one or more sugar modifications placed throughout the oligonucleotide so as to have no segment comprising more than 3 contiguous 2′-deoxynucleosides. In certain such embodiments, an oligonucleotide may have one or more sugar modifications placed throughout the oligonucleotide so as to have no segment comprising more than 2 contiguous 2′-deoxynucleosides.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a Ad₂Ad₂Ad₂Ad₂Ad₂A motif, wherein each A independently comprises a bicyclic modification selected from among LNA and cEt and each d comprises a 2′-deoxynucleoside.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a AAddAddAddAddAddAA motif, wherein each A independently comprises a bicyclic modification selected from among LNA and cEt and each d comprises a 2′-deoxynucleoside.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a AABBABBABBABBABBAB motif, wherein each A independently comprises a bicyclic modification selected from among LNA and cEt and each B independently comprises a 2′-modification selected from among a 2′-OMe, 2′-F, or 2′-MOE modification.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a AddAddAddAddAddA motif wherein each A independently comprises a bicyclic modification selected from among LNA and cEt and each d comprises a 2′-deoxynucleoside.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a keekeekeekeekeek motif, wherein each k comprises a cEt modification and each e comprises a 2′-MOE modification.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kd₂kd₂kd₂kd₂kd₂k motif, wherein each k comprises a cEt modification and each d comprises a 2′-deoxynucleoside.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kkddkddkddkddkddkk motif, wherein each k comprises a cEt modification and each d comprises a 2′-deoxynucleoside.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kkeekeekeekeekeeke motif, wherein each k comprises a cEt modification and each e comprises a 2′-MOE modification.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a kddkddkddkddkddk motif wherein each k comprises a cEt modification and each d comprises a 2′-deoxynucleoside.

In certain embodiments, the oligonucleotide compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a target nucleic acid, wherein the modified oligonucleotide comprises a keekeekeekeekeek motif, wherein each k comprises a cEt modification and each e comprises a 2′-MOE modification.

Certain Internucleoside Linkage Motifs

In certain embodiments, oligonucleotides comprise modified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or modified internucleoside linkage motif. In certain embodiments, internucleoside linkages are arranged in a gapped motif, as described above for sugar modification motif. In such embodiments, the internucleoside linkages in each of two wing regions are different from the internucleoside linkages in the gap region. In certain embodiments the internucleoside linkages in the wings are phosphodiester and the internucleoside linkages in the gap are phosphorothioate. The sugar modification motif is independently selected, so such oligonucleotides having a gapped internucleoside linkage motif may or may not have a gapped sugar modification motif and if it does have a gapped sugar motif, the wing and gap lengths may or may not be the same.

In certain embodiments, oligonucleotides comprise a region having an alternating internucleoside linkage motif. In certain embodiments, oligonucleotides of the present invention comprise a region of uniformly modified internucleoside linkages. In certain such embodiments, the oligonucleotide comprises a region that is uniformly linked by phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide is uniformly linked by phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate and at least one internucleoside linkage is phosphorothioate.

In certain embodiments, the oligonucleotide comprises at least 6 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 8 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 10 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 6 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 8 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 10 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least block of at least one 12 consecutive phosphorothioate internucleoside linkages. In certain such embodiments, at least one such block is located at the 3′ end of the oligonucleotide. In certain such embodiments, at least one such block is located within 3 nucleosides of the 3′ end of the oligonucleotide.

Certain Nucleobase Modification Motifs

In certain embodiments, oligonucleotides comprise chemical modifications to nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or nucleobases modification motif. In certain such embodiments, nucleobase modifications are arranged in a gapped motif. In certain embodiments, nucleobase modifications are arranged in an alternating motif. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases is chemically modified.

In certain embodiments, oligonucleotides comprise a block of modified nucleobases. In certain such embodiments, the block is at the 3′-end of the oligonucleotide. In certain embodiments the block is within 3 nucleotides of the 3′-end of the oligonucleotide. In certain such embodiments, the block is at the 5′-end of the oligonucleotide. In certain embodiments the block is within 3 nucleotides of the 5′-end of the oligonucleotide.

In certain embodiments, nucleobase modifications are a function of the natural base at a particular position of an oligonucleotide. For example, in certain embodiments each purine or each pyrimidine in an oligonucleotide is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each cytosine is modified. In certain embodiments, each uracil is modified.

In certain embodiments, some, all, or none of the cytosine moieties in an oligonucleotide are 5-methyl cytosine moieties. Herein, 5-methyl cytosine is not a “modified nucleobase.” Accordingly, unless otherwise indicated, unmodified nucleobases include both cytosine residues having a 5-methyl and those lacking a 5 methyl. In certain embodiments, the methylation state of all or some cytosine nucleobases is specified.

Certain Overall Lengths

In certain embodiments, the present invention provides oligomeric compounds including oligonucleotides of any of a variety of ranges of lengths. In certain embodiments, the invention provides oligomeric compounds or oligonucleotides consisting of X to Y linked nucleosides, where X represents the fewest number of nucleosides in the range and Y represents the largest number of nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50; provided that X≤Y. For example, in certain embodiments, the invention provides oligomeric compounds which comprise oligonucleotides consisting of 8 to 9, 8 to 10, 8 to 11, 8 to 12, 8 to 13, 8 to 14, 8 to 15, 8 to 16, 8 to 17, 8 to 18, 8 to 19, 8 to 20, 8 to 21, 8 to 22, 8 to 23, 8 to 24, 8 to 25, 8 to 26, 8 to 27, 8 to 28, 8 to 29, 8 to 30, 9 to 10, 9 to 11, 9 to 12, 9 to 13, 9 to 14, 9 to 15, 9 to 16, 9 to 17, 9 to 18, 9 to 19, 9 to 20, 9 to 21, 9 to 22, 9 to 23, 9 to 24, 9 to 25, 9 to 26, 9 to 27, 9 to 28, 9 to 29, 9 to 30, 10 to 11, 10 to 12, 10 to 13, 10 to 14, 10 to 15, 10 to 16, 10 to 17, 10 to 18, 10 to 19, 10 to 20, 10 to 21, 10 to 22, 10 to 23, 10 to 24, 10 to 25, 10 to 26, 10 to 27, 10 to 28, 10 to 29, 10 to 30, 11 to 12, 11 to 13, 11 to 14, 11 to 15, 11 to 16, 11 to 17, 11 to 18, 11 to 19, 11 to 20, 11 to 21, 11 to 22, 11 to 23, 11 to 24, 11 to 25, 11 to 26, 11 to 27, 11 to 28, 11 to 29, 11 to 30, 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12 to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25, 12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to 15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13 to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28, 13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to 19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14 to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17, 15 to 18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to 24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16 to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23, 16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to 30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17 to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30, 18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to 25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19 to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to 29, 19 to 28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to 24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21 to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28, 21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to 27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23 to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27, 24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to 29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27 to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked nucleosides. In embodiments where the number of nucleosides of an oligomeric compound or oligonucleotide is limited, whether to a range or to a specific number, the oligomeric compound or oligonucleotide may, nonetheless further comprise additional other substituents. For example, an oligonucleotide comprising 8-30 nucleosides excludes oligonucleotides having 31 nucleosides, but, unless otherwise indicated, such an oligonucleotide may further comprise, for example one or more conjugates, terminal groups, or other substituents. In certain embodiments, a gapmer oligonucleotide has any of the above lengths. In certain embodiments, an antisense oligonucleotide has any of the above lengths.

One of skill in the art will appreciate that certain lengths may not be possible for certain motifs. For example: a gapmer having a 5′-wing region consisting of four nucleotides, a gap consisting of at least six nucleotides, and a 3′-wing region consisting of three nucleotides cannot have an overall length less than 13 nucleotides. Thus, one would understand that the lower length limit is 13 and that the limit of 10 in “10-20” has no effect in that embodiment.

Further, where an oligonucleotide is described by an overall length range and by regions having specified lengths, and where the sum of specified lengths of the regions is less than the upper limit of the overall length range, the oligonucleotide may have additional nucleosides, beyond those of the specified regions, provided that the total number of nucleosides does not exceed the upper limit of the overall length range. For example, an oligonucleotide consisting of 20-25 linked nucleosides comprising a 5′-wing consisting of 5 linked nucleosides; a 3′-wing consisting of 5 linked nucleosides and a central gap consisting of 10 linked nucleosides (5+5+10=20) may have up to 5 nucleosides that are not part of the 5′-wing, the 3′-wing, or the gap (before reaching the overall length limitation of 25). Such additional nucleosides may be 5′ of the 5′-wing and/or 3′ of the 3′ wing.

Certain Oligonucleotides

In certain embodiments, oligonucleotides of the present invention are characterized by their sugar motif, internucleoside linkage motif, nucleobase modification motif and overall length. In certain embodiments, such parameters are each independent of one another. Thus, each internucleoside linkage of an oligonucleotide having a gapmer sugar motif may be modified or unmodified and may or may not follow the gapmer modification pattern of the sugar modifications. Thus, the internucleoside linkages within the wing regions of a sugar-gapmer may be the same or different from one another and may be the same or different from the internucleoside linkages of the gap region. Likewise, such sugar-gapmer oligonucleotides may comprise one or more modified nucleobase independent of the gapmer pattern of the sugar modifications. Herein if a description of an oligonucleotide or oligomeric compound is silent with respect to one or more parameter, such parameter is not limited. Thus, an oligomeric compound described only as having a gapmer sugar motif without further description may have any length, internucleoside linkage motif, and nucleobase modification motif. Unless otherwise indicated, all chemical modifications are independent of nucleobase sequence.

Certain Conjugate Groups

In certain embodiments, oligomeric compounds are modified by attachment of one or more conjugate groups. In general, conjugate groups modify one or more properties of the attached oligomeric compound including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, cellular distribution, cellular uptake, charge and clearance. Conjugate groups are routinely used in the chemical arts and are linked directly or via an optional conjugate linking moiety or conjugate linking group to a parent compound such as an oligomeric compound, such as an oligonucleotide. Conjugate groups includes without limitation, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins and dyes. Certain conjugate groups have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937).

In certain embodiments, a conjugate group comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

In certain embodiments, conjugate groups are directly attached to oligonucleotides in oligomeric compounds. In certain embodiments, conjugate groups are attached to oligonucleotides by a conjugate linking group. In certain such embodiments, conjugate linking groups, including, but not limited to, bifunctional linking moieties such as those known in the art are amenable to the compounds provided herein. Conjugate linking groups are useful for attachment of conjugate groups, such as chemical stabilizing groups, functional groups, reporter groups and other groups to selective sites in a parent compound such as for example an oligomeric compound. In general a bifunctional linking moiety comprises a hydrocarbyl moiety having two functional groups. One of the functional groups is selected to bind to a parent molecule or compound of interest and the other is selected to bind essentially any selected group such as chemical functional group or a conjugate group. In some embodiments, the conjugate linker comprises a chain structure or an oligomer of repeating units such as ethylene glycol or amino acid units. Examples of functional groups that are routinely used in a bifunctional linking moiety include, but are not limited to, electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In some embodiments, bifunctional linking moieties include amino, hydroxyl, carboxylic acid, thiol, unsaturations (e.g., double or triple bonds), and the like.

Some nonlimiting examples of conjugate linking moieties include pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other linking groups include, but are not limited to, substituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀ alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

Conjugate groups may be attached to either or both ends of an oligonucleotide (terminal conjugate groups) and/or at any internal position.

In certain embodiments, conjugate groups are at the 3′-end of an oligonucleotide of an oligomeric compound. In certain embodiments, conjugate groups are near the 3′-end. In certain embodiments, conjugates are attached at the 3′ end of an oligomeric compound, but before one or more terminal group nucleosides. In certain embodiments, conjugate groups are placed within a terminal group.

In certain embodiments, the present invention provides oligomeric compounds. In certain embodiments, oligomeric compounds comprise an oligonucleotide. In certain embodiments, an oligomeric compound comprises an oligonucleotide and one or more conjugate and/or terminal groups. Such conjugate and/or terminal groups may be added to oligonucleotides having any of the chemical motifs discussed above. Thus, for example, an oligomeric compound comprising an oligonucleotide having region of alternating nucleosides may comprise a terminal group.

Antisense Compounds

In certain embodiments, oligomeric compounds of the present invention are antisense compounds. Such antisense compounds are capable of hybridizing to a target nucleic acid, resulting in at least one antisense activity. In certain embodiments, antisense compounds specifically hybridize to one or more target nucleic acid. In certain embodiments, a specifically hybridizing antisense compound has a nucleobase sequence comprising a region having sufficient complementarity to a target nucleic acid to allow hybridization and result in antisense activity and insufficient complementarity to any non-target so as to avoid non-specific hybridization to any non-target nucleic acid sequences under conditions in which specific hybridization is desired (e.g., under physiological conditions for in vivo or therapeutic uses, and under conditions in which assays are performed in the case of in vitro assays).

In certain embodiments, the present invention provides antisense compounds comprising oligonucleotides that are fully complementary to the target nucleic acid over the entire length of the oligonucleotide. In certain embodiments, oligonucleotides are 99% complementary to the target nucleic acid. In certain embodiments, oligonucleotides are 95% complementary to the target nucleic acid. In certain embodiments, such oligonucleotides are 90% complementary to the target nucleic acid.

In certain embodiments, such oligonucleotides are 85% complementary to the target nucleic acid. In certain embodiments, such oligonucleotides are 80% complementary to the target nucleic acid. In certain embodiments, an antisense compound comprises a region that is fully complementary to a target nucleic acid and is at least 80% complementary to the target nucleic acid over the entire length of the oligonucleotide. In certain such embodiments, the region of full complementarity is from 6 to 14 nucleobases in length.

In certain embodiments antisense compounds and antisense oligonucleotides comprise single-strand compounds. In certain embodiments antisense compounds and antisense oligonucleotides comprise double-strand compounds.

Certain Pathways and Mechanisms Associated With Fibrosis

TGFβ1 and its associated pathways contribute to many processes associated with wound healing and tissue repair. After an injury, TGFβ1 contributes to the healing and restoration of normal tissue by, among other things, stimulating the production of certain extracellular matrix proteins and inhibiting the degradation of certain matrix proteins. In certain embodiments, TGFβ1 stimulates the production of fibronectin. In certain embodiments, TGFβ1 stimulates the production of both the EDA+ and EDA− isoforms of fibronectin. In certain embodiments, excessive amounts of the EDA+ fibronectin isoform causes tissue fibrosis. In certain embodiments, excessive tissue fibrosis induced by TGFβ1/EDA+ impairs normal organ function, impairs cellular function, and/or causes cells to change or lose their phenotype. In certain embodiments, the release and/or activation of TGFβ1 causes the formation of fibrosis and consequent changes in cell phenotype. In certain embodiments, changes in cell phenotype due to fibrosis include, but are not limited to, modulation of cadherin expression, induction of α Smooth Muscle Actin (αSMA), alteration of cortical f-actin localization, induction of connexin 43 (Cx 43) expression, alteration of vimentin, alteration of tight junction protein ZO-1, and/or increased secretion of MMP2 & MMP9. In certain embodiments, the release and/or activation of TGFβ1 causes a loss of cell phenotype. In certain embodiments, the loss of cell phenotype due to fibrosis impairs the structure or function of a cell. In certain embodiments, the loss of cell phenotype due to fibrosis destroys the function of a cell.

In certain embodiments, it is therefore desirable to reduce fibrosis without affecting the healing and/or restoration process. In certain embodiments, it is therefore desirable to reduce the formation of fibrosis in a cell without reducing or altering the amount and/or activity of TGFβ1 in the cell. In certain embodiments, it is therefore desirable to reduce the amount of EDA+ fibronectin in a cell without reducing or altering the amount of EDA− fibronectin in the cell. In certain embodiments, the reduction of the amount of EDA+ fibronectin in a cell in response to TGFβ1 will result in wound healing and tissue repair without incurring excessive fibrosis. In certain embodiments, the selective reduction of the amount of EDA+ fibronectin in a cell, relative to the amount of EDA− fibronectin in the cell in the response to TGFβ1 will stimulate wound healing and tissue repair without incurring changes in cell phenotype associated with fibrosis. In certain embodiments, the reduction of the amount of EDA+ fibronectin in a cell, relative to the amount of EDA− fibronectin in the cell in response to TGFβ1 will stimulate wound healing and tissue repair without incurring the loss of cell phenotype due to fibrosis.

In certain embodiments, it is desirable to reverse the formation of fibrosis in a cell without reducing or altering the wound healing function of TGFβ1 in the cell. In certain embodiments, it is therefore desirable to reverse the changes caused by fibrosis in the phenotype of a cell without reducing or altering the wound healing function of TGFβ1 in the cell. In certain embodiments, it is therefore desirable to reverse the loss of phenotype in a cell caused by fibrosis without reducing or altering the wound healing function of TGFβ1 in the cell.

Certain Target Nucleic Acids and Mechanisms

In certain embodiments, antisense compounds comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain embodiments, the target nucleic acid is a fibronectin transcript. In certain embodiments, the target RNA is a fibronectin pre-mRNA.

In certain embodiments, an antisense compound is complementary to a region of fibronectin pre-mRNA. In certain embodiments, an antisense compound is complementary within a region of fibronectin pre-mRNA comprising an exon encoding EDA. In certain embodiments, an antisense compound is complementary to a region of fibronectin pre-mRNA comprising an intron-exon splice junction. In certain embodiments, an antisense compound is complementary to a region of fibronectin pre-mRNA comprising the intron-exon splice junction adjacent to the EDA exon. In certain embodiments, an antisense compound is complementary within a region of fibronectin pre-mRNA consisting of an exon encoding EDA. In certain embodiments, an antisense compound is complementary within a region of fibronectin pre-mRNA comprising an exonic splicing silencer within an exon encoding EDA. In certain embodiments, an antisense compound is complementary within a region of fibronectin pre-mRNA comprising an exonic splicing enhancer within an exon encoding EDA.

In certain embodiments, an antisense compound comprises a modified oligonucleotide consisting of 8 to 30 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a fibronectin transcript. In certain embodiments, the target region is within nucleobase 55469 and nucleobase 55790 of SEQ ID NO.: 1. In certain embodiments, the target region is within nucleobase 55469 and nucleobase 55511 of SEQ ID NO.: 1. In certain embodiments, the target region is within nucleobase 55511 and nucleobase 55732 of SEQ ID NO.: 1. In certain embodiments, the target region is within nucleobase 55732 and nucleobase 55790 of SEQ ID NO.: 1.

In certain embodiments, an antisense oligonucleotide modulates splicing of a pre-mRNA. In certain embodiments, an antisense oligonucleotide modulates splicing a fibronectin pre-mRNA. In certain embodiments, an antisense oligonucleotide increases the amount of fibronectin mRNA. In certain embodiments, an antisense oligonucleotide increases the amount of EDA− fibronectin mRNA. In certain embodiments, an antisense oligonucleotide decreases the amount of EDA+ fibronectin mRNA. In certain embodiments, an antisense oligonucleotide decreases the amount of EDA+ fibronectin mRNA in the presence of TGFβ1. In certain embodiments, an antisense oligonucleotide decreases the amount of EDA+ fibronectin mRNA in a cell without substantially affecting the healing and/or restoration functions of the cell.

In certain embodiments, an antisense oligonucleotide alters the ratio of EDA+/EDA− fibronectin. In certain embodiments, an antisense oligonucleotide increases the ratio of EDA+/EDA− fibronectin. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin to create a fibrosis model. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin to create a fibrosis phenotype. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis model. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis phenotype. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin to create a fibrosis mouse model. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin to create a fibrosis mouse phenotype. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis mouse model. In certain embodiments, it is desirable to increase the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis mouse phenotype.

In certain embodiments, an antisense oligonucleotide alters the ratio of EDA+/EDA− fibronectin. In certain embodiments, an antisense oligonucleotide decreases the ratio of EDA+/EDA− fibronectin. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin to create a fibrosis model. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin to create a fibrosis phenotype. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis model. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis phenotype. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin to create a fibrosis mouse model. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin to create a fibrosis mouse phenotype. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis mouse model. In certain embodiments, it is desirable to decrease the ratio of EDA+/EDA− fibronectin in the presence of TGFβ1 to create a fibrosis mouse phenotype.

In certain embodiments, an antisense oligonucleotide alters the ratio of EDA−/EDA+ fibronectin. In certain embodiments, an antisense oligonucleotide increases the ratio of EDA−/EDA+ fibronectin. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin to create a fibrosis model. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin to create a fibrosis phenotype. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis model. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis phenotype. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin to create a fibrosis mouse model. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin to create a fibrosis mouse phenotype. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis mouse model. In certain embodiments, it is desirable to increase the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis mouse phenotype.

In certain embodiments, an antisense oligonucleotide alters the ratio of EDA−/EDA+ fibronectin. In certain embodiments, an antisense oligonucleotide decreases the ratio of EDA−/EDA+ fibronectin. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin to create a fibrosis model. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin to create a fibrosis phenotype. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis model. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis phenotype. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin to create a fibrosis mouse model. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin to create a fibrosis mouse phenotype. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis mouse model. In certain embodiments, it is desirable to decrease the ratio of EDA−/EDA+ fibronectin in the presence of TGFβ1 to create a fibrosis mouse phenotype.

Certain Pharmaceutical Compositions

In certain embodiments, the present invention provides pharmaceutical compositions comprising one or more antisense compound. In certain embodiments, such pharmaceutical composition comprises a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutical composition comprises a sterile saline solution and one or more antisense compound. In certain embodiments, such pharmaceutical composition consists of a sterile saline solution and one or more antisense compound. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, a pharmaceutical composition comprises one or more antisense compound and sterile water. In certain embodiments, a pharmaceutical composition consists of one or more antisense compound and sterile water. In certain embodiments, the sterile saline is pharmaceutical grade water. In certain embodiments, a pharmaceutical composition comprises one or more antisense compound and phosphate-buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one or more antisense compound and sterile phosphate-buffered saline (PBS). In certain embodiments, the sterile saline is pharmaceutical grade PBS.

In certain embodiments, antisense compounds may be admixed with pharmaceutically acceptable active and/or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions depend on a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters. In certain embodiments, pharmaceutical compositions comprising antisense compounds comprise one or more oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

A prodrug can include the incorporation of additional nucleosides at one or both ends of an oligomeric compound which are cleaved by endogenous nucleases within the body, to form the active antisense oligomeric compound.

Lipid moieties have been used in nucleic acid therapies in a variety of methods. In certain such methods, the nucleic acid is introduced into preformed liposomes or lipoplexes made of mixtures of cationic lipids and neutral lipids. In certain methods, DNA complexes with mono- or poly-cationic lipids are formed without the presence of a neutral lipid. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to a particular cell or tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to fat tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to muscle tissue.

In certain embodiments, pharmaceutical compositions provided herein comprise one or more modified oligonucleotides and one or more excipients. In certain such embodiments, excipients are selected from water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone.

In certain embodiments, a pharmaceutical composition provided herein comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.

In certain embodiments, a pharmaceutical composition provided herein comprises one or more tissue-specific delivery molecules designed to deliver the one or more pharmaceutical agents of the present invention to specific tissues or cell types. For example, in certain embodiments, pharmaceutical compositions include liposomes coated with a tissue-specific antibody.

In certain embodiments, a pharmaceutical composition provided herein comprises a co-solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

In certain embodiments, a pharmaceutical composition provided herein is prepared for oral administration. In certain embodiments, pharmaceutical compositions are prepared for buccal administration.

In certain embodiments, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, such suspensions may also contain suitable stabilizers or agents that increase the solubility of the pharmaceutical agents to allow for the preparation of highly concentrated solutions.

In certain embodiments, a pharmaceutical composition is prepared for transmucosal administration. In certain of such embodiments penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

In certain embodiments, a pharmaceutical composition provided herein comprises an oligonucleotide in a therapeutically effective amount. In certain embodiments, the therapeutically effective amount is sufficient to prevent, alleviate or ameliorate symptoms of a disease or to prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art.

In certain embodiments, one or more modified oligonucleotide provided herein is formulated as a prodrug. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically more active form of an oligonucleotide. In certain embodiments, prodrugs are useful because they are easier to administer than the corresponding active form. For example, in certain instances, a prodrug may be more bioavailable (e.g., through oral administration) than is the corresponding active form. In certain instances, a prodrug may have improved solubility compared to the corresponding active form. In certain embodiments, prodrugs are less water soluble than the corresponding active form. In certain instances, such prodrugs possess superior transmittal across cell membranes, where water solubility is detrimental to mobility. In certain embodiments, a prodrug is an ester. In certain such embodiments, the ester is metabolically hydrolyzed to carboxylic acid upon administration. In certain instances the carboxylic acid containing compound is the corresponding active form. In certain embodiments, a prodrug comprises a short peptide (polyaminoacid) bound to an acid group. In certain of such embodiments, the peptide is cleaved upon administration to form the corresponding active form.

In certain embodiments, the present invention provides compositions and methods for reducing the amount or activity of a target nucleic acid in a cell. In certain embodiments, the cell is in an animal. In certain embodiments, the animal is a mammal. In certain embodiments, the animal is a rodent. In certain embodiments, the animal is a primate. In certain embodiments, the animal is a non-human primate. In certain embodiments, the animal is a human.

In certain embodiments, the present invention provides methods of administering a pharmaceutical composition comprising an oligomeric compound of the present invention to an animal. Suitable administration routes include, but are not limited to, oral, rectal, transmucosal, intestinal, enteral, topical, suppository, through inhalation, intrathecal, intracerebroventricular, intraperitoneal, intranasal, intraocular, intratumoral, and parenteral (e.g., intravenous, intramuscular, intramedullary, and subcutaneous). In certain embodiments, pharmaceutical intrathecals are administered to achieve local rather than systemic exposures. For example, pharmaceutical compositions may be injected directly in the area of desired effect (e.g., into the eyes, ears).

In certain embodiments, a pharmaceutical composition is administered to an animal having at least one symptom associated with fibrosis. In certain embodiments, such administration results in amelioration of at least one symptom. In certain embodiments, administration of a pharmaceutical composition to an animal results in a decrease of EDA+ fibronectin mRNA in a cell of the animal. In certain embodiments, such administration results in an increase in EDA− fibronectin mRNA. In certain embodiments, such administration results in a decrease in EDA+ fibronectin protein and an increase EDA− fibronectin protein. In certain embodiments, a fibronectin protein lacking EDA amino acids is preferred over a fibronectin protein having EDA amino acids. In certain embodiments, the administration of certain antisense oligonucleotides delays the onset of fibrosis. In certain embodiments, the administration of certain antisense oligonucleotides slows the progression of fibrosis. In certain embodiments, the administration of certain antisense oligonucleotides prevents the formation of fibrosis. In certain embodiments, the administration of certain antisense oligonucleotides reverses fibrosis. In certain embodiments, the administration of certain antisense oligonucleotides rescues cellular phenotype. In certain embodiments, the administration of certain antisense oligonucleotides rescues cellular morphology.

Nonlimiting Disclosure and Incorporation by Reference

While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.

Although the sequence listing accompanying this filing identifies each sequence as either “RNA” or “DNA” as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as “RNA” or “DNA” to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2′-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2′-OH for the natural 2′-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) for natural uracil of RNA).

Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleobase sequence “ATCGATCG” encompasses any oligomeric compounds having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as “AUCGATCG” and oligomeric compounds having other modified or naturally occurring bases, such as “AT^(me)CGAUCG,” wherein ^(me)C indicates a cytosine base comprising a methyl group at the 5-position.

EXAMPLES

The following examples illustrate certain embodiments of the present invention and are not limiting. Moreover, where specific embodiments are provided, the inventors have contemplated generic application of those specific embodiments. For example, disclosure of an oligonucleotide having a particular motif provides reasonable support for additional oligonucleotides having the same or similar motif. And, for example, where a particular high-affinity modification appears at a particular position, other high-affinity modifications at the same position are considered suitable, unless otherwise indicated.

Example 1: In Vitro Screening of Human Fibronectin Splicing with Antisense Oligonucleotides in HKC-8 Cells

Antisense oligonucleotides were designed targeting a fibronectin nucleic acid and were tested for their effects on the alternative splicing of the fibronectin gene sequence in vitro. The newly designed antisense oligonucleotides in Table 1 were designed as uniform MOE oligonucleotides. Each nucleoside in the oligonucleotide has a 2′-MOE modification. The internucleoside linkages throughout each oligonucleotide are phosphorothioate (P═S) linkages. All cytosine residues throughout each oligonucleotide are 5-methylcytosines. “Start site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted in the human gene sequence. “Stop site” indicates the 3′-most nucleoside to which the oligonucleotide is targeted human gene sequence. Each oligonucleotide listed in Table 1 is targeted to SEQ ID NO: 1 (the complement of GENBANK Accession No. NT_005403.14 truncated from nucleotides 66434501 to 66510708). ISIS 141923 (CCTTCCCTGAAGGTTCCTCC (SEQ ID NO: 25), no known human target) was used as a negative control.

Cultured HKC-8 cells, which are SV40-transformed human proximal tubular cells, were transfected using 3 μL LipofectAMINE2000®/mL OptiMEM with 200 nM antisense oligonucleotide. After a treatment period of approximately 4 hours, the medium was removed and new medium was added, left in culture overnight. RNA was isolated from the cells and the ratio of Extra Domain A positive fibronectin (EDA⁺FN) to EDA negative fibronectin (EDA⁻FN) was measured by conventional PCR. Human primers with forward sequence GGAGAGAGTCAGCCTCTGGTTCAG, designated herein as SEQ ID NO: 2; reverse sequence TGTCAACTGGGCGCTCAGGCTTGTG, designated herein as SEQ ID NO: 3) was used to measure mRNA levels. To compare the efficacy of antisense treatments performed in different experiments and allow for inter-assay variability, ratios were indexed on the corresponding negative control. Results are presented in Table 1 and demonstrate that treatment with antisense oligonucleotides targeted to the EDA region of fibronectin resulted in decreased expression of the EDA⁺FN isoform compared to the negative control. ‘null’ indicates that the EDA⁺ band was undetectable for that sample.

TABLE 1 Ratio of EDA⁺FN to EDA⁻FN in HKC-8 cells after treatment with antisense oligonucleotides targeted to SEQ ID NO: 1 ISIS SEQ ID NO: 1 SEQ ID NO: 1 EDA⁺FN/ SEQ NO Start Site Stop Site Sequence EDA⁻FN ID NO 511399 55469 55483 GCAAATTAATGGTAA 0.07  5 511400 55473 55487 TTAGGCAAATTAATG 0.07  6 511401 55477 55491 TCTGTTAGGCAAATT 0.05  7 511402 55480 55494 ATGTCTGTTAGGCAA 0.09  8 511403 55483 55497 TCAATGTCTGTTAGG 0.04  9 511404 55486 55500 CGATCAATGTCTGTT 0.04 10 511405 55489 55503 GGGCGATCAATGTCT 0.03 11 511406 55493 55507 TTTAGGGCGATCAAT 0.03 12 511407 55497 55511 GTCCTTTAGGGCGAT 0.4 13 511408 55732 55746 CCAATCAGGGGCTGG 0.02 14 511409 55736 55750 GGTTCCAATCAGGGG null 15 511410 55740 55754 ACTGGGTTCCAATCA 0.01 16 511411 55743 55757 TGGACTGGGTTCCAA 0.02 17 511412 55746 55760 CTGTGGACTGGGTTC null 18 511413 55749 55763 TACCTGTGGACTGGG 0.06 19 511414 55752 55766 ATATACCTGTGGACT 0.04 20 511415 55756 55770 AACCATATACCTGTG 0.05 21 511416 55760 55774 AATTAACCATATACC 0.15 22 511417 55482 55499 GATCAATGTCTGTTAGGC 0.12 23 511418 55744 55761 CCTGTGGACTGGGTTCCA null 24 141923 n/a n/a CCTTCCCTGAAGGTTCCTCC 1.00 25

Example 2: In Vitro Screening of Human Fibronectin Splicing with Antisense Oligonucleotides in Primary Human Proximal Tubular Cells

The antisense oligonucleotides described in Example 1 were also tested for their effects on the alternative splicing of the fibronectin gene sequence in primary human proximal tubular cells (PTEC). Cultured PTEC cells were transfected using 2 μL LipofectAMINE2000®/mL OptiMEM with 100 nM antisense oligonucleotide for 4 hours, the medium was removed and new medium added, left in culture overnight, and then treated with 0.1% BSA (vehicle) or 2.5 ng/mL TGFβ1 in 0.1% BSA for 24 hrs. RNA was isolated from the cells and levels were measured by conventional PCR. The ratio of EDA⁺FN to EDA⁻FN for the given oligonucleotide-treated cells to the ratio for the negative control-treated cells was calculated. Results are presented in Table 2 and indicate that treatment with antisense oligonucleotides targeted to the EDA region of fibronectin resulted in decreased expression of the EDA⁺FN isoform compared to the negative control, even after induction with TGFβ1. ‘null’ indicates that the EDA⁺ band was undetectable for that sample.

TABLE 2 Ratio of EDA⁺FN to EDA⁻FN in PTEC cells after treatment with antisense oligonucleotides EDA⁺FN/ EDA⁺FN/ EDA⁻FN EDA⁻FN (without (with SEQ ID ISIS NO TGFβ1) TGFβ1) NO 511399 0.13 0.17 5 511400 0.23 0.26 6 511401 0.14 0.26 7 511402 0.20 0.27 8 511403 0.13 0.23 9 511404 0.09 0.11 10 511405 0.06 0.08 11 511406 0.03 0.04 12 511407 0.41 0.66 13 511408 null null 14 511409 null null 15 511410 null null 16 511411 0.10 0.09 17 511412 null null 18 511413 0.08 0.09 19 511414 0.15 0.13 20 511415 0.34 0.42 21 511416 0.62 0.97 22 511417 0.17 0.20 23 511418 null null 24 141923 1.00 1.61 25

Example 3: Effect of Antisense Oligonucleotides Targeting the EDA Region of Fibronectin on TGFβ1 Induction of EDA⁺FN mRNA Expression in Primary Human Proximal Tubular Cells

Antisense oligonucleotides selected from the studies described above were tested for their effects on the alternative splicing of the fibronectin gene sequence in primary human proximal tubular cells (PTEC) treated with TGFβ1. One set of cultured PTEC cells were transfected using 2 μL LipofectAMINE2000®/mL OptiMEM with 100 nM antisense oligonucleotide. These cells were treated for 4 hours with antisense oligonucleotide; the medium was removed and new medium added; left in culture overnight; and then treated with 0.1% BSA (vehicle) or 2.5 ng/mL TGFβ1 in 0.1% BSA for 24 hrs. These cells were designated as pre-TGFβ1. Another set of cells were first treated with 0.1% BSA (vehicle) or 2.5 ng/mL TGFβ1 in 01% BSA for 24 hrs; then transfected using 2 μL LipofectAMINE2000®/mL OptiMEM with 100 nM antisense oligonucleotide for 4 h; the medium was removed and new medium added; and then left in culture overnight. These cells were designated as post-TGFβ1. RNA was isolated from the cells and levels were measured by conventional PCR. The ratio of EDA⁺FN to EDA⁻FN for the given oligonucleotide-treated cells to the ratio for the negative control-treated cells was calculated. Results are presented in Tables 3 and 4, and indicate that treatment with antisense oligonucleotides targeted to the EDA region of fibronectin resulted in decreased expression of the EDA⁺FN isoform compared to the negative control, irrespective of whether the treatment with antisense oligonucleotides took place before or after induction with TGFβ1 ‘null’ indicates that the EDA⁺ band was undetectable for that sample.

TABLE 3 Ratio of EDA⁺FN to EDA⁻FN in pre- TGFβ1 PTEC cells after treatment with antisense oligonucleotides EDA⁺FN/ EDA⁺FN/ EDA⁻FN EDA⁻FN (without (with SEQ ID ISIS NO TGFβ1) TGFβ1) NO 511399 0.13 0.17 5 511403 0.13 0.23 9 511407 0.41 0.66 13 511408 null null 14 511412 null null 18 511416 0.62 0.97 22 141923 1.00 1.61 25

TABLE 4 Ratio of EDA⁺FN to EDA⁻FN in post-TGFβ1 PTEC cells after treatment with antisense oligonucleotides EDA⁺FN/ EDA⁺FN/ EDA⁻FN EDA⁻FN (without (with SEQ ID ISIS NO TGFβ1) TGFβ1) NO 511399 0.68 0.75 5 511403 0.48 0.30 9 511407 0.68 0.68 13 511408 0.22 0.16 14 511412 null null 18 511416 0.79 0.69 22 141923 1.00 1.57 25

Example 4: Effect of Antisense Oligonucleotides Targeting the EDA Region of Fibronectin on TGFβ1 Induction of EDA⁺FN Protein Expression in Primary Human Proximal Tubular Cells

The antisense oligonucleotides described above were tested for their effects on the alternative splicing of the fibronectin gene sequence in primary human proximal tubular cells (PTEC) treated with TGFβ1. Cultured PTEC cells were transfected using 2 μL LipofectAMINE2000/mL OptiMEM with 100 nM antisense oligonucleotide. The cells were treated for 4 hours with antisense oligonucleotide; the medium was removed and new medium added; left in culture overnight; and then treated with 0.1% BSA (vehicle) or 2.5 ng/mL TGFβ1 in 01% BSA for 48 hrs. The cells were lysed in lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X, 0.5% sodium deoxycholate, 0.1% SDS; pH 7.2) and protein was extracted as described in Phanish M K et al., Biochem J. 2006 Jan. 15; 393(Pt 2):601-7. The protein samples were run on an SDS-PAGE and analyzed via western analysis using the anti-Fibronectin antibody [IST-9] (Abcam, ab6328) that reacts with an epitope located in the ED-A sequence of cellular fibronectin. Results are presented in Table 5, and indicate that treatment with antisense oligonucleotides targeted to the EDA region of fibronectin resulted in decreased protein expression of the EDA⁺FN isoform compared to the negative control.

TABLE 5 EDA⁺FN expression in PTEC cells after treatment with antisense oligonucleotides (densitometric analysis on one Western blot) EDA⁺FN EDA⁺FN (without (with SEQ ID ISIS NO TGFβ1) TGFβ1) NO 511399 0.07 0.03 5 511403 0.02 0.04 9 511407 0.13 0.75 13 511408 0.08 0.77 14 511412 0.25 0.30 18 511416 0.61 0.58 22 141923 0.31 0.74 25

Example 5: Effect of ISIS 511403 on TGFβ1 Induction of Fibrosis in Primary Human Proximal Tubular Cells

ISIS 511403 was tested for its effect on the alternative splicing of the fibronectin gene sequence in primary human proximal tubular cells (PTEC) treated with TGFβ1. Cultured PTEC cells were treated with 0.1% BSA (vehicle) or with 2.5 ng/mL TGFβ1 in 01% BSA for 24 hrs and then transfected using 2 μL LipofectAMINE2000®/mL OptiMEM with 100 nM ISIS 511403 or 100 nM ISIS 141923 for 24 h. After a recovery period of 24 h in normal growth medium, RNA was isolated and the ratio of EDA⁺FN to EDA_(□)FN was measured by conventional PCR. In addition, the individual expressions of EDA⁺FN and EDA^(−□)FN normalized to 18s RNA were also measured (human primer probe set for 18S: forward sequence: GTAACCCGTTGAACCCCATT (SEQ ID NO: 26), reverse sequence: CCATCCAATCGGTAGTAGCG (SEQ ID NO: 27)). In addition, the expression of total fibronectin was also measured by quantitative real-time PCR (probe set Hs01549940_m1, Applied Biosystems). The results are presented in Table 6 and indicate that treatment with ISIS 511403 decreased the ratio of EDA⁺FN to EDA⁻FN, decreased expression of EDA⁺FN, increased expression of EDA⁻FN, and had no effect on total fibronectin expression compared to that of the negative control cells.

TABLE 6 Effect of ISIS 511403 in PTEC cells treated with TGFβ1 without with TGFβ1 TGFβ1 EDA⁺FN/ ISIS 141923 0.90 1.54 EDA^(−□)FN ISIS 511403 0.21 0.12 EDA⁺FN/18S ISIS 141923 0.21 0.21 ISIS 511403 0.07 0.68 EDA^(−□)FN/18S ISIS 141923 0.23 0.11 ISIS 511403 0.32 0.86 Total ISIS 141923 1.00 (0.82-1.23) 3.98 (3.60-4.40) Fibronectin (range) ISIS 511403 1.37 (1.17-1.60) 4.14 (4.05-4.23)

The effect of treatment with ISIS 511403 on lactate dehydrogenase (LDH) release by the cells was also measured using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, G1780). The results are presented in Table 7 and indicate the decrease in LDH release in cells treated with ISIS 511403 compared to the cells treated with the negative control. This demonstrates that ISIS 511403 can rescue certain pronounced changes in cell phenotype caused by TGFβ1 induction, e.g. the release of LDH.

TABLE 7 Effect of ISIS 511403 on LDH release in PTEC cells treated with TGFβ1 Absorbance at 490 nm ISIS 141923 without TGFβ1 0.14 with TGFβ1 0.12 ISIS 511403 without TGFβ1 0.33 with TGFβ1 0.16

The effect of treatment with ISIS 511403 on αSMA mRNA expression by the cells was also measured by quantitative real-time PCR, using primer probe set Hs00909449_m1 (Applied Biosystems). The results are presented in Table 8 and indicate the decrease in αSMA in cells treated with ISIS 511403 compared to the cells treated with the negative control. The numbers in parentheses indicate the range. This demonstrates that ISIS 511403 can rescue certain pronounced changes in cell phenotype caused by TGFβ1 induction, e.g. the induction of αSMA.

TABLE 8 Effect of ISIS 511403 on αSMA expression in PTEC cells treated with TGFβ1 Fold increase over basal levels ISIS 141923 without TGFβ1 1.00 (0.79-1.26) with TGFβ1 1.96 (1.70-2.25) ISIS 511403 without TGFβ1 0.70 (0.59-0.83) with TGFβ1 0.79 (0.68-0.91)

The data presented in Tables 7 and 8 indicate that treatment with antisense oligonucleotides inhibiting the splicing and inclusion of the EDA region of fibronectin resulted in decreased fibrosis in primary human PTEC and therefore have therapeutic benefit in the prevention, treatment, or amelioration of fibrosis.

Additionally, by staining it was observed that prevention of EDA inclusion by treatment with ISIS 511403 resulted in a significant reduction in αSMA compared to treatment with a control (ISIS 141923). By western blot analysis, it was also observed that prevention of EDA inclusion by treatment with ISIS 511403 resulted in reduction in secretion of MMP2 & MMP9. The fold-change in the cell motility marker, S 100A4 was measured and is presented in Table 9. Treatment with ISIS 511403 resulted in significant reduction in S100A4 in TGF-β-treated cells.

TABLE 9 Effect of ISIS 511403 on S100A4 expression in PTEC cells treated with TGFβ1 Fold increase over basal levels ISIS 141923 without TGFβ1 1.00 with TGFβ1 1.45 ISIS 511403 without TGFβ1 0.62 with TGFβ1 0.74

By staining and by western blot analysis, it was also observed that prevention of EDA inclusion by treatment with ISIS 511403 resulted in near complete inhibition of Connexin 43. By staining, it was also observed that prevention of EDA inclusion by treatment with ISIS 511403 resulted in a moderate increase in f-actin localization.

Example 6: Design of Antisense Oligonucleotides Targeting Human and Murine Fibronectin

Antisense oligonucleotides were designed targeting a fibronectin nucleic acid. The newly designed chimeric antisense oligonucleotides in Table 10 were designed as uniform MOE oligonucleotides. Each nucleoside in the oligonucleotide has a 2′-MOE modification. The internucleoside linkages throughout each oligonucleotide are phosphorothioate (P═S) linkages. All cytosine residues throughout each oligonucleotide are 5-methylcytosines. “Human Start site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted in the human gene sequence. “Murine Start Site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted murine gene sequence. Each oligonucleotide listed in Table 10 is targeted to the human fibronectin genomic sequence, SEQ ID NO: 1 (the complement of GENBANK Accession No. NT_005403.14 truncated from nucleotides 66434501 to 66510708) or to murine fibronectin genomic sequence, SEQ ID NO: 29 (the complement of Accession No. NT_039170.2 truncated from nucleotides 20696091 to 20764741), or both. Several of the oligonucleotides are cross-reactive with human and mouse gene sequences. The greater the complementarity between the oligonucleotide and the gene sequence, the more likely the oligonucleotide can target the gene sequence. ‘Mismatches’ indicates the number of nucleotides in the oligonucleotide that are mismatched with the gene sequence. ‘n/a’ indicates that the oligonucleotide contains more than 2 mismatches with the particular gene sequence.

TABLE 10 Antisense oligonucleotides targeted to SEQ ID NO: 1 and SEQ ID NO: 29 Human target Mismatches Mouse Target Mismatches SEQ ID Start Site with SEQ Start Site with SEQ NO of (SEQ ID NO: 1) ID NO: 1 Sequence ISIS No (SEQ ID NO: 29) ID NO: 29) oligo 55458 0 GTAAGAGGTTATGTG 594692 49712 0 30 55464 0 TTAATGGTAAGAGGT 594693 49718 0 31 55478 0 AATGTCTGTTAGGCAAAT 594685 49732 0 32 55479 0 CAATGTCTGTTAGGCAAA 594686 49733 0 33 55480 0 TCAATGTCTGTTAGGCAA 594687 49734 0 34 55481 0 AATGTCTGTTAGGCA 594681 49735 0 35 55481 0 ATCAATGTCTGTTAGGCA 594688 49735 0 36 55482 0 CAATGTCTGTTAGGC 594682 49736 0 37 55483 0 CGATCAATGTCTGTTAGG 594689 49737 0 38 55484 0 ATCAATGTCTGTTAG 594683 49738 0 39 55484 0 GCGATCAATGTCTGTTAG 594690 49738 0 40 55485 0 GATCAATGTCTGTTA 594684 49739 0 41 55485 0 GGCGATCAATGTCTGTTA 594691 49739 0 42 55501 0 GCCAGTCCTTTAGGG 594694 49755 0 43 55507 0 GTGAATGCCAGTCCT 594695 49761 0 44 55513 0 ACATCAGTGAATGCC 594696 49767 0 45 55519 0 ACATCCACATCAGTG 594697 49773 0 46 55525 0 GAATCGACATCCACA 594698 49779 0 47 55531 0 TTGATGGAATCGACA 594699 49785 0 48 55537 0 GCAATTTTGATGGAA 594700 49791 0 49 55543 0 TCCCAAGCAATTTTG 594701 49797 0 50 55549 0 GGGCTTTCCCAAGCA 594702 49803 0 51 55555 0 CCCTGTGGGCTTTCC 594703 49809 0 52 55561 0 ACTTGCCCCTGTGGG 594704 49815 0 53 55567 0 CTGGAAACTTGCCCC 594705 49821 0 54 55573 0 CTGTACCTGGAAACT 594706 49827 0 55 55579 0 GTCACCCTGTACCTG 594707 49833 0 56 55585 0 GAGTAGGTCACCCTG 594708 49839 0 57 55591 0 GGGCTCGAGTAGGTC 594709 49845 0 58 55597 0 TCCTCAGGGCTCGAG 594710 49851 0 59 55603 0 ATTCCATCCTCAGGG 594711 49857 0 60 55609 0 TCATGGATTCCATCC 594712 49863 2 61 55615 0 AATAGCTCATGGATT 594713 n/a n/a 62 55621 0 GCAGGGAATAGCTCA 594714 49875 2 63 55627 0 TCAGGTGCAGGGAAT 594715 49881 1 64 55633 0 TCACCATCAGGTGCA 594716 49887 0 65 55639 0 TCTTCTTCACCATCA 594717 49893 1 66 55645 0 GCAGTGTCTTCTTCA 594718 49899 1 67 55651 0 AGCTCTGCAGTGTCT 594719 49905 1 68 55657 0 CCTTGCAGCTCTGCA 594720 49911 1 69 55663 0 CTGAGGCCTTGCAGC 594721 49917 1 70 55669 0 CCCGGTCTGAGGCCT 594722 49923 2 71 55675 0 TCAGAACCCGGTCTG 594723 49929 2 72 55681 0 GTGTACTCAGAACCC 594724 49935 1 73 55687 0 CTGACTGTGTACTCA 594725 49941 0 74 55693 0 ACCACACTGACTGTG 594726 49947 0 75 55699 0 AAGGCAACCACACTG 594727 49953 0 76 55705 0 TCGTGCAAGGCAACC 594728 49959 0 77 55711 0 ATATCATCGTGCAAG 594729 49965 0 78 55717 0 CTCTCCATATCATCG 594730 49971 0 79 55723 0 GGCTGGCTCTCCATA 594731 49977 0 80 55736 1 GATTCCAATCAGGGG 594670 49990 0 81 55740 1 ACTGGATTCCAATCA 594671 49994 0 82 55743 1 TGGACTGGATTCCAA 594672 49997 0 83 55744 1 CCTGTGGACTGGATTCCA 594677 49998 0 84 55746 1 CTGTGGACTGGATTC 594673 50000 0 85 55749 1 TACCTGTGGACTGGA 594674 50003 0 86 55756 1 AACGATATACCTGTG 594675 50010 0 87 55760 2 AATTAATCATAAACC 594676 39337 0 88 55765 0 GGTGCAATTAACCAT 594732 n/a n/a 89 55771 0 CCTGGTGGTGCAATT 594733 n/a n/a 90

Example 7: In Vitro Screening of Uniform MOE Antisense Oligonucleotides Targeting Human and/or Mouse Fibronectin in MHT Cells

Some of the antisense oligonucleotides presented in Example 6 were tested for potency in cultured primary PTEC cells. ISIS 511403 was also included in the study.

Cultured PTEC cells were transfected using 2 μL LipofectAMINE2000/mL OptiMEM with 100 nM antisense oligonucleotide for 4 hours, the medium was removed and new medium added, left in culture overnight, and then treated with 0.1% BSA (vehicle) or 2.5 ng/mL TGFβ1 in 0.1% BSA for 24 hrs. RNA was isolated from the cells and levels of EDA⁺FN mRNA were measured by RT-PCR using primer probe sets RTS3963_MGB (forward sequence GCCTTGCACGATGATATGGA, designated herein as SEQ ID NO: 91; reverse sequence TGTGGGTGTGACCTGAGTGAA, designated herein as SEQ ID NO: 92; probe sequence ATTGGAACCCAGTCCAC, designated herein as SEQ ID NO: 93), as well as with primer probe set RTS3964 (forward sequence GAATCCAAGCGGAGAGAGTCA, designated herein as SEQ ID NO: 94; reverse sequence ACATCAGTGAATGCCAGTCCTTT, designated herein as SEQ ID NO: 95; probe sequence TTCAGACTGCAGTAACCAACATTGATCGCC, designated herein as SEQ ID NO: 96), both of which are designed to the EDA+ variant of the FN mRNA transcript (NM_212478.1, designated herein as SEQ ID NO: 97) and which target different regions of the transcript. For data analysis, the levels of EDA⁺FN mRNA were normalized to the levels of the house-keeping gene, the large ribosomal protein transcript (Human RPLPO, Applied Biosystems, cat#4333761F). For each antisense oligonucleotide, the ratio of EDA⁺FN to RPLPO in antisense oligonucleotide-treated cells was then normalized to the ratio of EDA⁺FN mRNA to RPLPO in untreated cells. The results are presented in Table 11. The results indicate that treatment with antisense oligonucleotides reduced expression of the EDA+ transcript compared to untreated cells, both in the presence or absence of TGFβ1.

TABLE 11 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) in primary PTEC cells without with ISIS No PPset Used TGFβ1 TGFβ1 511403 RTS3963_MGB 0.21 0.21 594692 RTS3963_MGB 0.17 0.29 594693 RTS3963_MGB 0.21 0.32 594694 RTS3963_MGB 0.02 0.03 594695 RTS3963_MGB 0.15 0.24 594696 RTS3963_MGB 0.23 0.41 594697 RTS3963_MGB 0.40 0.70 594698 RTS3963_MGB 0.50 0.81 594699 RTS3963_MGB 0.51 0.76 594700 RTS3963_MGB 0.13 0.18 594701 RTS3963_MGB 0.33 0.47 594702 RTS3963_MGB 0.30 0.49 594703 RTS3963_MGB 0.16 0.32 594704 RTS3963_MGB 0.56 0.73 594705 RTS3963_MGB 0.40 0.68 594706 RTS3963_MGB 0.40 0.81 594707 RTS3963_MGB 0.29 0.40 594708 RTS3963_MGB 0.06 0.05 594709 RTS3963_MGB 0.03 0.02 594710 RTS3963_MGB 0.18 0.16 594711 RTS3963_MGB 0.43 0.27 594712 RTS3963_MGB 0.36 0.31 594713 RTS3963_MGB 0.14 0.15 594714 RTS3963_MGB 0.06 0.08 594715 RTS3963_MGB 0.05 0.07 594716 RTS3963_MGB 0.18 0.16 594717 RTS3963_MGB 0.71 0.68 594718 RTS3963_MGB 0.22 0.33 594719 RTS3963_MGB 0.46 0.44 594720 RTS3963_MGB 0.13 0.14 594721 RTS3963_MGB 0.14 0.13 594722 RTS3963_MGB 0.07 0.15 594723 RTS3963_MGB 0.05 0.05 594724 RTS3963_MGB 0.11 0.17 594725 RTS3963_MGB 0.06 0.07 594726 RTS3963_MGB 0.12 0.17 594727 RTS3964 0.06 0.10 594728 RTS3964 0.03 0.02 594729 RTS3964 0.08 0.06 594730 RTS3964 0.39 0.38 594731 RTS3964 0.10 0.07 594732 RTS3963_MGB 0.92 0.79 594733 RTS3963_MGB 0.37 0.38

Example 8: In Vitro Screening of Uniform MOE Antisense Oligonucleotides Targeting Human and/or Mouse Fibronectin in MHT Cells

Antisense oligonucleotides were designed targeting a fibronectin nucleic acid and were tested for their effects on blocking of splicing in vitro. The newly designed chimeric antisense oligonucleotides in Table 12 were designed as uniform MOE oligonucleotides. Each oligonucleotide is 15 nucleosides long and each nucleoside in the oligonucleotide has a 2′-MOE modification. The internucleoside linkages throughout each oligonucleotide are phosphorothioate (P═S) linkages. All cytosine residues throughout each oligonucleotide are 5-methylcytosines. “Human Start site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted in the human gene sequence. “Murine Start Site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted murine gene sequence. Each oligonucleotide listed in Table 12 is targeted to the human fibronectin genomic sequence, SEQ ID NO: 1 or to murine fibronectin genomic sequence, SEQ ID NO: 22, or both. Several of the oligonucleotides are cross-reactive with human and mouse gene sequences. The greater the complementarity between the oligonucleotide and the gene sequence, the more likely the oligonucleotide can target the gene sequence. ‘Mismatches’ indicates the least number of nucleotides in the oligonucleotide that are mismatched with the gene sequence; the antisense oligonucleotide may target the gene sequence with more mismatches. ‘n/a’ indicates that the antisense oligonucleotide has more than 3 mismatches with the particular gene sequence.

Cultured MHT cells, a mouse hepatocellular carcinoma cell line (Koller, E. et al., Nucleic Acids Research, 2011, 1-13), were transfected using 5 μl LipofectAMINE2000®/mL OptiMEM with 50 nM antisense oligonucleotide. After a treatment period of approximately 4 hours, the medium was removed and new medium was added, and the cells were left in culture overnight. RNA was isolated from the cells and measured by RT-PCR. EDA⁺FN mRNA expression was measured with mouse primer probe set LTS01050 (forward sequence AAACTGCAGTGACCAACATTGATC, designated herein as SEQ ID NO: 98; reverse sequence CTTGCCCCTGTGGGCTTT, designated herein as SEQ ID NO: 99; probe sequence CTGATGTGGATGTCGATT, designated herein as SEQ ID NO: 100), as well as with LTS01052 (forward sequence GCCAGCCCCTGATTGGA, designated herein as SEQ ID NO: 101; reverse sequence CCGGTAGCCAGTGAGCTGAA, designated herein as SEQ ID NO: 102; probe sequence CACCAATCTGAAGTTC, designated herein as SEQ ID NO: 103). The primer probe sets target different regions of the mouse sequence.

Results are presented in Table 12 and are the average of the values measured in three separate experiments. The results demonstrate blocking of splicing, as represented by EDA⁺FN expression. The expression value of untreated cells was taken as 1.00. ‘n.d.’ indicates that the mRNA expression level values were not considered because the oligonucleotide targeted an amplicon region of the specific primer probe set.

TABLE 12 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in MHT cells Mis- % % Human matches Mouse inhibition inhibition SEQ Start with Start ISIS with with ID Site human Sequence Site No LTS01050 LTS01052 NO 55469 0 GCAAATTAATGGTAA 49723 511399  0.43 0.44 104 55486 0 CGATCAATGTCTGTT 49740 511404 n.d. 0.27 105 55746 1 CTGTGGACTGGATTC 50000 594673  0.61 n.d.  85 55756 1 AACGATATACCTGTG 50010 594675  0.28 n.d.  87 55481 0 AATGTCTGTTAGGCA 49735 594681 n.d. 0.37  35 55501 0 GCCAGTCCTTTAGGG 49755 594694 n.d. 0.46  43 55531 0 TTGATGGAATCGACA 49785 594699 n.d. 0.93  48 55561 0 ACTTGCCCCTGTGGG 49815 594704 n.d. 0.94  53 55591 0 GGGCTCGAGTAGGTC 49845 594709  0.18 0.37  58 55711 0 ATATCATCGTGCAAG 49965 594729  0.50 0.33  78 55418 3 TCCATACCATGCAAA 49670 598110  1.11 1.04 106 20288 3 ATATTTCCATACCAT 49675 598111  1.11 1.02 107 51489 3 17531 3 CAAGCATATTTCCAT 49680 598112  0.93 1.03 108 19804 3 23642 3 42202 3 43710 2 TGAAACAAGCATATT 49685 598113  1.04 1.15 109 55431 2 55436 1 AGTTGTGAAACAAGC 49690 598114  0.42 0.58 110 55441 0 AAGCAAGTTGTGAAA 49695 598115  0.08 0.35 111 55446 0 GTGAAAAGCAAGTTG 49700 598116  0.85 0.94 112 55451 0 GTTATGTGAAAAGCA 49705 598117  0.63 0.68 113 55456 0 AAGAGGTTATGTGAA 49710 598118  0.58 0.54 114 55461 0 ATGGTAAGAGGTTAT 49715 598119  0.47 0.43 115 55466 0 AATTAATGGTAAGAG 49720 598120  0.49 0.53 116 55471 0 AGGCAAATTAATGGT 49725 598121  0.27 0.29 117 55476 0 CTGTTAGGCAAATTA 49730 598122  0.23 0.34 118 55491 0 TAGGGCGATCAATGT 49745 598123 n.d. 0.29 119 55496 0 TCCTTTAGGGCGATC 49750 598124 n.d. 0.39 120 55506 0 TGAATGCCAGTCCTT 49760 598125 n.d. 0.70 121 55511 0 ATCAGTGAATGCCAG 49765 598126 n.d. 0.54 122 55516 0 TCCACATCAGTGAAT 49770 598127 n.d. 0.53 123 55521 0 CGACATCCACATCAG 49775 598128 n.d. 0.47 124 55526 0 GGAATCGACATCCAC 49780 598129 n.d. 0.32 125 55536 0 CAATTTTGATGGAAT 49790 598130 n.d. 0.26 126 55541 0 CCAAGCAATTTTGAT 49795 598131 n.d. 0.45 127 55546 0 CTTTCCCAAGCAATT 49800 598132 n.d. 0.51 128 55551 0 GTGGGCTTTCCCAAG 49805 598133 n.d. 0.92 129 55556 0 CCCCTGTGGGCTTTC 49810 598134 n.d. 0.59 130 55566 0 TGGAAACTTGCCCCT 49820 598135 n.d. 0.70 131 55571 0 GTACCTGGAAACTTG 49825 598136 n.d. 0.50 132 55576 0 ACCCTGTACCTGGAA 49830 598137 78    0.27 133 55581 0 AGGTCACCCTGTACC 49835 598138 78    0.27 134 55586 0 CGAGTAGGTCACCCT 49840 598139 71    0.41 135 55596 0 CCTCAGGGCTCGAGT 49850 598140 73    0.42 136 55601 0 TCCATCCTCAGGGCT 49855 598141 63    0.42 137 55606 1 CGGATTCCATCCTCA 49860 598142 52    0.35 138 55611 2 GCTCCCGGATTCCAT 49865 598143 78    0.31 139 48384 3 GAAAAGCTCCCGGAT 49870 598144  0.20 0.28 140 55616 3 55621 2 GCAGGGAAAAGCTCC 49875 598145  0.19 0.21 141 55626 1 CAGGTGCAGGGAAAA 49880 598146  0.32 0.33 142 55631 0 ACCATCAGGTGCAGG 49885 598147  0.31 0.30 143 55636 0 TCTTCACCATCAGGT 49890 598148  0.47 0.38 144 55641 1 TGTCGTCTTCACCAT 49895 598149  0.39 0.37 145 55646 1 TGCAGTGTCGTCTTC 49900 598150  0.66 0.41 146 55651 1 AGCTCTGCAGTGTCG 49905 598151  0.29 0.24 147 55656 1 CCTGCAGCTCTGCAG 49910 598152  0.40 0.42 148 55661 1 GAGGCCCTGCAGCTC 49915 598153  0.25 0.21 149 55666 2 GGCCTGAGGCCCTGC 49920 598154  0.79 0.80 150 55671 2 ACCCCGGCCTGAGGC 49925 598155  0.48 0.54 151 55676 2 CTCAGACCCCGGCCT 49930 598156  0.68 0.76 152 55681 1 GTGTACTCAGACCCC 49935 598157  0.57 0.41 153 55686 0 TGACTGTGTACTCAG 49940 598158  0.56 0.54 154 55691 0 CACACTGACTGTGTA 49945 598159  0.59 0.51 155 55696 0 GCAACCACACTGACT 49950 598160  0.54 0.49 156 55701 0 GCAAGGCAACCACAC 49955 598161  0.27 0.27 157 55706 0 ATCGTGCAAGGCAAC 49960 598162  0.56 0.49 158 55716 0 TCTCCATATCATCGT 49970 598163  0.31 0.22 159 55721 0 CTGGCTCTCCATATC 49975 598164  0.66 n.d. 160 55741 1 GACTGGATTCCAATC 49995 598165  0.56 n.d. 161 55751 0 TATACCTGTGGACTG 50005 598166  0.39 n.d. 162 55761 3 CGGTTAACGATATAC 50015 598167  0.30 0.25 163 n/a n/a GGGTGCGGTTAACGA 50020 598168  0.91 0.95 164 n/a n/a GTGGTGGGTGCGGTT 50025 598169  0.95 0.51 165  7620 3 CCCGGGTGGTGGGTG 50030 598170  0.81 0.79 166 n/a n/a AAGCACCCGGGTGGT 50035 598171  0.92 1.00 167 n/a n/a CCCAGAAGCACCCGG 50040 598172  1.36 1.32 168 50882 3 CTGTTCCCAGAAGCA 50045 598173  1.44 1.41 169 23948 1 AGCCACTGTTCCCAG 50050 598174  1.11 1.14 170 47171 1 55796 2 CATAAAGCCACTGTT 50055 598175  0.94 0.91 171 64745 2 55801 3 CAAGGCATAAAGCCA 50060 598176  1.13 0.97 172 n/a n/a GCCAGCAAGGCATAA 50065 598177  0.78 0.95 173 61226 3 ATAACGCCAGCAAGG 50070 598178  1.08 1.10 174 n/a n/a AAAGTATAACGCCAG 50075 598179  1.13 1.08 175  3323 3 CCAGTAAAGTATAAC 50080 598180  1.09 1.20 176 55824 3 60705 3

Example 9: Antisense Inhibition of Fibronectin mRNA in MHT Cells by Uniform MOE Oligonucleotides Designed by Microwalk

Additional antisense oligonucleotides were designed based on the ISIS oligonucleotides that demonstrated significant effect on fibronectin splicing in the studies described above. These oligonucleotides were designed by creating oligonucleotides shifted slightly upstream and downstream (i.e. “microwalk”) of ISIS 511417, ISIS 594685, ISIS 594686, ISIS 594686, ISIS 594687, ISIS 594688, ISIS 594689, ISIS 594690, ISIS 594691, and ISIS 598145. The newly designed antisense oligonucleotides in Tables 13 and 14 were designed as uniform MOE oligonucleotides. Each oligonucleotide is 18 nucleosides long and each nucleoside in the oligonucleotide has a 2′-MOE modification. The internucleoside linkages throughout each oligonucleotide are phosphorothioate (P═S) linkages. All cytosine residues throughout each oligonucleotide are 5-methylcytosines. The oligonucleotides are presented in the tables below. “Human Start site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted in the human gene sequence. “Murine Start Site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted murine gene sequence. Each oligonucleotide listed in the tables is targeted to the human fibronectin genomic sequence, SEQ ID NO: 1 or to murine fibronectin genomic sequence, SEQ ID NO: 29, or both. Several of the oligonucleotides are cross-reactive with human and mouse gene sequences. The greater the complementarity between the oligonucleotide and the gene sequence, the more likely the oligonucleotide can target the gene sequence. ‘Mismatches’ indicates the least number of nucleotides in the oligonucleotide that are mismatched with the gene sequence; the antisense oligonucleotide may target the gene sequence with more mismatches. ‘n/a’ indicates that the antisense oligonucleotide has more than 3 mismatches with the particular gene sequence. Cultured MHT cells were transfected using 5 μl LipofectAMINE2000®/mL OptiMEM with 10 nM antisense oligonucleotide. After a treatment period of approximately 4 hours, the medium was removed and new medium was added, left in culture overnight. RNA was isolated from the cells and measured by RT-PCR. EDA⁺FN mRNA expression was measured with mouse primer probe set LTS01050, as well as with LTS01052.

Results are presented in Tables 13 and 14, and are the average of the values measured in three separate experiments. The results demonstrate blocking of splicing, as represented by EDA⁺FN expression. The expression value of untreated cells was taken as 1.00. ‘n.d.’ indicates that the mRNA expression level values were not considered because the oligonucleotide targeted an amplicon region of the specific primer probe set.

TABLE 13 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in MHT cells Human Mismatches Murine SEQ Start with human ISIS Start ID Site sequence Sequence No Site LTS01050 LTS01052 NO 55471 0 GTTAGGCAAATTAATGGT 606663 49725 n.d. 0.77 177 55472 0 TGTTAGGCAAATTAATGG 606664 49726 n.d. 0.80 178 55473 0 CTGTTAGGCAAATTAATG 606665 49727 n.d. 0.78 179 55474 0 TCTGTTAGGCAAATTAAT 606666 49728 n.d. 0.73 180 55475 0 GTCTGTTAGGCAAATTAA 606667 49729 n.d. 0.70 181 55476 0 TGTCTGTTAGGCAAATTA 606668 49730 n.d. 0.62 182 55477 0 ATGTCTGTTAGGCAAATT 606669 49731 n.d. 0.66 183 55478 0 AATGTCTGTTAGGCAAAT 594685 49732 n.d. 0.79  32 55479 0 CAATGTCTGTTAGGCAAA 594686 49733 0.57 0.50  33 55480 0 TCAATGTCTGTTAGGCAA 594687 49734 1.21 0.99  34 55481 0 ATCAATGTCTGTTAGGCA 594688 49735 1.04 0.83  36 55482 0 GATCAATGTCTGTTAGGC 511417 49736 0.70 0.63 184 55483 0 CGATCAATGTCTGTTAGG 594689 49737 n.d. 0.66  38 55484 0 GCGATCAATGTCTGTTAG 594690 49738 n.d. 0.64  40 55485 0 GGCGATCAATGTCTGTTA 594691 49739 n.d. 0.85  42 55486 0 GGGCGATCAATGTCTGTT 606670 49740 n.d. 0.83 185 55487 0 AGGGCGATCAATGTCTGT 606671 49741 n.d. 0.82 186 55488 0 TAGGGCGATCAATGTCTG 606672 49742 n.d. 0.80 187 55489 0 TTAGGGCGATCAATGTCT 606673 49743 n.d. 0.56 188 55490 0 TTTAGGGCGATCAATGTC 606674 49744 n.d. 0.56 189 55491 0 CTTTAGGGCGATCAATGT 606675 49745 n.d. 0.55 190 55492 0 CCTTTAGGGCGATCAATG 606676 49746 n.d. 0.47 191 55493 0 TCCTTTAGGGCGATCAAT 606677 49747 n.d. 0.57 192 55494 0 GTCCTTTAGGGCGATCAA 606678 49748 n.d. 0.62 193 55495 0 AGTCCTTTAGGGCGATCA 606679 49749 n.d. 0.94 194 55496 0 CAGTCCTTTAGGGCGATC 606680 49750 n.d. 0.92 195 55523 0 GGAATCGACATCCACATC 606681 49777 n.d. 0.68 196 55524 0 TGGAATCGACATCCACAT 606682 49778 n.d. 0.70 197 55525 0 ATGGAATCGACATCCACA 606683 49779 n.d. 0.66 198 55526 0 GATGGAATCGACATCCAC 606684 49780 n.d. 0.63 199 55527 0 TGATGGAATCGACATCCA 606685 49781 n.d. 0.63 200 55528 0 TTGATGGAATCGACATCC 606686 49782 n.d. 0.88 201 55529 0 TTTGATGGAATCGACATC 606687 49783 n.d. 0.93 202 55533 0 CAATTTTGATGGAATCGA 606688 49787 n.d. 1.05 203 55534 0 GCAATTTTGATGGAATCG 606689 49788 n.d. 0.81 204 55535 0 AGCAATTTTGATGGAATC 606690 49789 n.d. 0.60 205 55536 0 AAGCAATTTTGATGGAAT 606691 49790 n.d. 0.66 206 55537 0 CAAGCAATTTTGATGGAA 606692 49791 n.d. 0.56 207 55538 0 CCAAGCAATTTTGATGGA 606693 49792 n.d. 0.61 208 55539 0 CCCAAGCAATTTTGATGG 606694 49793 n.d. 0.84 209 55576 0 GTCACCCTGTACCTGGAA 606695 49830 n.d. 0.88 210 55577 0 GGTCACCCTGTACCTGGA 606696 49831 1.32 1.07 211 55578 0 AGGTCACCCTGTACCTGG 606697 49832 0.74 0.81 212 55579 0 TAGGTCACCCTGTACCTG 606698 49833 0.61 0.69 213 55580 0 GTAGGTCACCCTGTACCT 606699 49834 0.52 0.49 214 55581 0 AGTAGGTCACCCTGTACC 606700 49835 0.48 0.57 215 55582 0 GAGTAGGTCACCCTGTAC 606701 49836 0.45 0.59 216 55583 0 CGAGTAGGTCACCCTGTA 606702 49837 0.60 0.80 217 55584 0 TCGAGTAGGTCACCCTGT 606703 49838 0.60 0.91 218 55585 0 CTCGAGTAGGTCACCCTG 606704 49839 0.60 0.78 219 55586 0 GCTCGAGTAGGTCACCCT 606705 49840 0.59 0.69 220 55587 0 GGCTCGAGTAGGTCACCC 606706 49841 0.57 0.57 221 55588 0 GGGCTCGAGTAGGTCACC 606707 49842 0.53 0.58 222 55589 0 AGGGCTCGAGTAGGTCAC 606708 49843 0.62 0.63 223 55590 0 CAGGGCTCGAGTAGGTCA 606709 49844 0.45 0.50 224 55591 0 TCAGGGCTCGAGTAGGTC 606710 49845 0.60 0.60 225 55592 0 CTCAGGGCTCGAGTAGGT 606711 49846 0.83 0.86 226 55593 0 CCTCAGGGCTCGAGTAGG 606712 49847 0.95 0.99 227 55594 0 TCCTCAGGGCTCGAGTAG 606713 49848 0.95 0.83 228 55595 0 ATCCTCAGGGCTCGAGTA 606714 49849 0.67 0.61 229 55596 0 CATCCTCAGGGCTCGAGT 606715 49850 0.58 0.59 230 55597 0 CCATCCTCAGGGCTCGAG 606716 49851 0.65 0.58 231 55598 0 TCCATCCTCAGGGCTCGA 606717 49852 0.64 0.54 232 55599 0 TTCCATCCTCAGGGCTCG 606718 49853 0.65 0.62 233 55600 0 ATTCCATCCTCAGGGCTC 606719 49854 0.87 0.88 234 55601 0 GATTCCATCCTCAGGGCT 606720 49855 0.87 0.82 235 55602 0 GGATTCCATCCTCAGGGC 606721 49856 0.53 0.66 236 55603 1 CGGATTCCATCCTCAGGG 606722 49857 0.48 0.51 237 55604 2 CCGGATTCCATCCTCAGG 606723 49858 0.58 0.50 238 55605 2 CCCGGATTCCATCCTCAG 606724 49859 0.53 0.49 239 55606 2 TCCCGGATTCCATCCTCA 606725 49860 0.51 0.53 240 55607 2 CTCCCGGATTCCATCCTC 606726 49861 0.61 0.62 241 55608 2 GCTCCCGGATTCCATCCT 606727 49862 0.68 0.75 242 55609 2 AGCTCCCGGATTCCATCC 606728 49863 0.83 0.90 243 55610 3 AAGCTCCCGGATTCCATC 606729 49864 0.48 0.68 244 55611 3 AAAGCTCCCGGATTCCAT 606730 49865 0.26 0.53 245 55612 3 AAAAGCTCCCGGATTCCA 606731 49866 0.32 0.52 246 55613 3 GAAAAGCTCCCGGATTCC 606732 49867 0.37 0.52 247 55614 3 GGAAAAGCTCCCGGATTC 606733 49868 0.49 0.59 248 55615 3 GGGAAAAGCTCCCGGATT 606734 49869 0.61 0.57 249 55621 2 GCAGGGAAAAGCTCC 598145 49875 0.78 0.92 141

TABLE 14 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in MHT cells Human Mismatches Murine SEQ Start with human ISIS Start ID Site sequence Sequence No Site LTS01050 LTS01052 NO 48384 3 AGGGAAAAGCTCCCGGAT 606735 49870 0.95 0.77 250 55617 3 CAGGGAAAAGCTCCCGGA 606736 49871 1.04 0.83 251 55618 3 GCAGGGAAAAGCTCCCGG 606737 49872 0.85 0.82 252 55619 3 TGCAGGGAAAAGCTCCCG 606738 49873 0.71 0.76 253 55620 3 GTGCAGGGAAAAGCTCCC 606739 49874 0.65 0.68 254 55621 2 GCAGGGAAAAGCTCC 598145 49875 0.79 0.55 141 55621 2 GGTGCAGGGAAAAGCTCC 606740 49875 0.79 0.76 255 55622 1 AGGTGCAGGGAAAAGCTC 606741 49876 0.88 0.83 256 55623 1 CAGGTGCAGGGAAAAGCT 606742 49877 0.77 0.88 257 55624 1 TCAGGTGCAGGGAAAAGC 606743 49878 1.11 0.98 258 55625 1 ATCAGGTGCAGGGAAAAG 606744 49879 1.05 0.97 259 55626 1 CATCAGGTGCAGGGAAAA 606745 49880 0.76 0.79 260 55627 1 CCATCAGGTGCAGGGAAA 606746 49881 0.50 0.63 261 55628 0 ACCATCAGGTGCAGGGAA 606747 49882 0.53 0.73 262 55629 0 CACCATCAGGTGCAGGGA 606748 49883 0.70 0.77 263 55630 0 TCACCATCAGGTGCAGGG 606749 49884 0.83 0.85 264 55631 0 TTCACCATCAGGTGCAGG 606750 49885 1.11 0.94 265 55632 0 CTTCACCATCAGGTGCAG 606751 49886 0.88 0.82 266 55633 0 TCTTCACCATCAGGTGCA 606752 49887 0.68 0.71 267 55634 1 GTCTTCACCATCAGGTGC 606753 49888 0.49 0.55 268 55635 1 CGTCTTCACCATCAGGTG 606754 49889 0.90 0.53 269 55636 1 TCGTCTTCACCATCAGGT 606755 49890 1.17 0.49 270 55637 1 GTCGTCTTCACCATCAGG 606756 49891 1.58 0.57 271 55638 1 TGTCGTCTTCACCATCAG 606757 49892 1.48 0.64 272 55639 1 GTGTCGTCTTCACCATCA 606758 49893 1.27 0.96 273 55640 1 AGTGTCGTCTTCACCATC 606759 49894 0.78 0.75 274 55641 1 CAGTGTCGTCTTCACCAT 606760 49895 0.52 0.54 275 55642 1 GCAGTGTCGTCTTCACCA 606761 49896 0.47 0.53 276 55643 1 TGCAGTGTCGTCTTCACC 606762 49897 0.49 0.55 277 55644 1 CTGCAGTGTCGTCTTCAC 606763 49898 0.61 0.54 278 55645 1 TCTGCAGTGTCGTCTTCA 606764 49899 0.93 0.57 279 55646 1 CTCTGCAGTGTCGTCTTC 606765 49900 0.98 0.67 280 55647 1 GCTCTGCAGTGTCGTCTT 606766 49901 0.72 0.83 281 55648 1 AGCTCTGCAGTGTCGTCT 606767 49902 0.71 0.65 282 55649 1 CAGCTCTGCAGTGTCGTC 606768 49903 0.71 0.62 283 55650 1 GCAGCTCTGCAGTGTCGT 606769 49904 0.64 0.60 284 55651 1 TGCAGCTCTGCAGTGTCG 606770 49905 0.40 0.47 285 55652 1 CTGCAGCTCTGCAGTGTC 606771 49906 0.35 0.53 286 55653 1 CCTGCAGCTCTGCAGTGT 606772 49907 0.47 0.56 287 55654 1 CCCTGCAGCTCTGCAGTG 606773 49908 0.71 0.97 288 55655 1 GCCCTGCAGCTCTGCAGT 606774 49909 0.83 0.97 289 55656 1 GGCCCTGCAGCTCTGCAG 606775 49910 0.91 0.73 290 55657 1 AGGCCCTGCAGCTCTGCA 606776 49911 0.74 0.64 291 55658 1 GAGGCCCTGCAGCTCTGC 606777 49912 0.60 0.66 292 55659 1 TGAGGCCCTGCAGCTCTG 606778 49913 0.49 0.50 293 55660 1 CTGAGGCCCTGCAGCTCT 606779 49914 0.47 0.57 294 55661 2 CCTGAGGCCCTGCAGCTC 606780 49915 0.54 0.65 295 55698 0 GCAAGGCAACCACACTGA 606781 49952 0.60 0.71 296 55699 0 TGCAAGGCAACCACACTG 606782 49953 0.75 0.79 297 55700 0 GTGCAAGGCAACCACACT 606783 49954 0.75 0.63 298 55701 0 CGTGCAAGGCAACCACAC 606784 49955 0.53 0.59 299 55702 0 TCGTGCAAGGCAACCACA 606785 49956 0.46 0.46 300 55703 0 ATCGTGCAAGGCAACCAC 606786 49957 0.48 0.55 301 55704 0 CATCGTGCAAGGCAACCA 606787 49958 0.46 0.45 302 55708 0 ATATCATCGTGCAAGGCA 606788 49962 0.36 0.45 303 55709 0 CATATCATCGTGCAAGGC 606789 49963 0.59 0.49 304 55710 0 CCATATCATCGTGCAAGG 606790 49964 1.00 0.72 305 55711 0 TCCATATCATCGTGCAAG 606791 49965 1.00 0.58 306 55712 0 CTCCATATCATCGTGCAA 606792 49966 0.78 0.54 307 55713 0 TCTCCATATCATCGTGCA 606793 49967 0.61 0.46 308 55714 0 CTCTCCATATCATCGTGC 606794 49968 0.52 n.d. 309 55715 0 GCTCTCCATATCATCGTG 606795 49969 0.69 n.d. 310 55716 0 GGCTCTCCATATCATCGT 606796 49970 0.70 n.d. 311 55717 0 TGGCTCTCCATATCATCG 606797 49971 0.71 n.d. 312 55718 0 CTGGCTCTCCATATCATC 606798 49972 1.37 n.d. 313 55719 0 GCTGGCTCTCCATATCAT 606799 49973 1.82 n.d. 314 55749 1 ATATACCTGTGGACTGGA 606800 50003 0.77 n.d. 315 55750 1 GATATACCTGTGGACTGG 606801 50004 0.56 n.d. 316 55751 1 CGATATACCTGTGGACTG 606802 50005 0.40 n.d. 317 55752 1 ACGATATACCTGTGGACT 606803 50006 0.34 n.d. 318 55753 1 AACGATATACCTGTGGAC 606804 50007 0.33 n.d. 319 55754 1 TAACGATATACCTGTGGA 606805 50008 0.47 n.d. 320 55755 1 TTAACGATATACCTGTGG 606806 50009 0.57 n.d. 321 55756 2 GTTAACGATATACCTGTG 606807 50010 0.73 n.d. 322 55757 3 GGTTAACGATATACCTGT 606808 50011 0.59 n.d. 323 55758 3 CGGTTAACGATATACCTG 606809 50012 0.40 n.d. 324 55759 3 GCGGTTAACGATATACCT 606810 50013 0.40 n.d. 325 55760 3 TGCGGTTAACGATATACC 606811 50014 0.40 n.d. 326 55761 3 GTGCGGTTAACGATATAC 606812 50015 0.43 0.46 327 55762 3 GGTGCGGTTAACGATATA 606813 50016 0.48 0.59 328 n/a n/a GGGTGCGGTTAACGATAT 606814 50017 0.77 0.83 329

Example 10: In Vitro Screening of Antisense Oligonucleotides with (S)-cEt Modifications Targeting Human and/or Mouse Fibronectin in b.END Cells

Antisense oligonucleotides were designed targeting a fibronectin nucleic acid and were tested for their effects on blocking of fibronectin splicing in vitro. ISIS 606793 was also included in the study. The newly designed antisense oligonucleotides in Tables 15-22 were designed as deoxy and (S)-cEt oligonucleotides. Each nucleoside in the oligonucleotide has a 2′-MOE, deoxy, or (S)-cEt modification, as presented in the Chemistry column of the tables. ‘e’ indicates MOE; ‘k’ indicates (S)-cEt; ‘d’ indicates deoxy modifications. The internucleoside linkages throughout each oligonucleotide are phosphorothioate (P═S) linkages. All cytosine residues throughout each oligonucleotide are 5-methylcytosines. “Human Start site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted in the human gene sequence. “Murine Start Site” indicates the 5′-most nucleoside to which the oligonucleotide is targeted murine gene sequence. Each oligonucleotide listed in Tables 15-22 is targeted to the human fibronectin genomic sequence, SEQ ID NO: 1 or to murine fibronectin genomic sequence, SEQ ID NO: 29, or both. Several of the oligonucleotides are cross-reactive with human and mouse gene sequences. The greater the complementarity between the oligonucleotide and the gene sequence, the more likely the oligonucleotide can target the gene sequence. ‘Mismatches’ indicates the least number of nucleotides in the oligonucleotide that are mismatched with the gene sequence; the antisense oligonucleotide may target the gene sequence with more mismatches. ‘n/a’ indicates that the antisense oligonucleotide has more than 3 mismatches with the particular gene sequence.

Cultured b.END cells were transfected using 2 μl Cytofectin/mL with 3 nM antisense oligonucleotide. After a treatment period of approximately 4 hours, the medium was removed and new medium was added, left in culture overnight. RNA was isolated from the cells and measured by RT-PCR. EDA⁺FN mRNA expression was measured with mouse primer probe set LTS01050, as well as with LTS01052.

Results are presented in Tables 15-22, and are the average of the values measured in three separate experiments. The results demonstrate blocking of splicing, as represented by EDA⁺FN expression. The expression value of untreated cells was taken as 1.00. ‘n.d.’ indicates that the mRNA expression level values were not considered because the oligonucleotide targeted an amplicon region of the specific primer probe set.

TABLE 15 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01050 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 48386 3 49872 AGGGAAAAGCTCCCGG 607180 kddkddkddkddkddk 0.80 330 55578 0 49832 GTCACCCTGTACCTGG 607170 kddkddkddkddkddk 0.86 331 55582 0 49836 GTAGGTCACCCTGTAC 607171 kddkddkddkddkddk 0.71 332 55586 0 49840 TCGAGTAGGTCACCCT 607172 kddkddkddkddkddk 0.56 333 55590 0 49844 GGGCTCGAGTAGGTCA 607173 kddkddkddkddkddk 0.41 334 55594 0 49848 CTCAGGGCTCGAGTAG 607174 kddkddkddkddkddk 0.50 335 55598 0 49852 CATCCTCAGGGCTCGA 607175 kddkddkddkddkddk 0.44 336 55602 0 49856 ATTCCATCCTCAGGGC 607176 kddkddkddkddkddk 0.42 337 55606 2 49860 CCGGATTCCATCCTCA 607177 kddkddkddkddkddk 0.47 338 55610 2 49864 GCTCCCGGATTCCATC 607178 kddkddkddkddkddk 0.18 339 55614 3 49868 AAAAGCTCCCGGATTC 607179 kddkddkddkddkddk 0.31 340 55622 1 49876 GTGCAGGGAAAAGCTC 607181 kddkddkddkddkddk 0.73 341 55626 1 49880 TCAGGTGCAGGGAAAA 607182 kddkddkddkddkddk 0.72 342 55630 0 49884 ACCATCAGGTGCAGGG 607183 kddkddkddkddkddk 0.36 343 55634 0 49888 CTTCACCATCAGGTGC 607184 kddkddkddkddkddk 0.49 344 55638 1 49892 TCGTCTTCACCATCAG 607185 kddkddkddkddkddk 0.34 345 55642 1 49896 AGTGTCGTCTTCACCA 607186 kddkddkddkddkddk 0.22 346 55646 1 49900 CTGCAGTGTCGTCTTC 607187 kddkddkddkddkddk 0.36 347 55650 1 49904 AGCTCTGCAGTGTCGT 607188 kddkddkddkddkddk 0.19 348 55654 1 49908 CTGCAGCTCTGCAGTG 607189 kddkddkddkddkddk 0.71 349 55658 1 49912 GGCCCTGCAGCTCTGC 607190 kddkddkddkddkddk 0.29 350 55662 1 49916 CTGAGGCCCTGCAGCT 607191 kddkddkddkddkddk 0.32 351 55666 2 49920 CGGCCTGAGGCCCTGC 607192 kddkddkddkddkddk 0.48 352 55670 2 49924 ACCCCGGCCTGAGGCC 607193 kddkddkddkddkddk 0.33 353 55674 2 49928 TCAGACCCCGGCCTGA 607194 kddkddkddkddkddk 0.34 354 55678 2 49932 GTACTCAGACCCCGGC 607195 kddkddkddkddkddk 0.27 355 55682 1 49936 CTGTGTACTCAGACCC 607196 kddkddkddkddkddk 0.63 356 55686 0 49940 CTGACTGTGTACTCAG 607197 kddkddkddkddkddk 0.61 357 55690 0 49944 CACACTGACTGTGTAC 607198 kddkddkddkddkddk 0.57 358 55694 0 49948 CAACCACACTGACTGT 607199 kddkddkddkddkddk 0.51 359 55698 0 49952 AAGGCAACCACACTGA 607200 kddkddkddkddkddk 0.47 360 55702 0 49956 GTGCAAGGCAACCACA 607201 kddkddkddkddkddk 0.28 361 55706 0 49960 CATCGTGCAAGGCAAC 607202 kddkddkddkddkddk 0.27 362 55710 0 49964 ATATCATCGTGCAAGG 607203 kddkddkddkddkddk 0.44 363 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.13 308 55714 0 49968 CTCCATATCATCGTGC 607204 kddkddkddkddkddk 0.18 364 55718 0 49972 GGCTCTCCATATCATC 607205 kddkddkddkddkddk 0.22 365 55722 0 49976 GGCTGGCTCTCCATAT 607206 kddkddkddkddkddk 0.53 366 55738 1 49992 CTGGATTCCAATCAGG 607207 kddkddkddkddkddk 0.17 367 55742 1 49996 TGGACTGGATTCCAAT 607208 kddkddkddkddkddk 0.17 368 55746 1 50000 CCTGTGGACTGGATTC 607209 kddkddkddkddkddk 0.23 369 55750 0 50004 TATACCTGTGGACTGG 607210 kddkddkddkddkddk 0.24 370 55754 1 50008 ACGATATACCTGTGGA 607211 kddkddkddkddkddk 0.51 371 55758 2 50012 GTTAACGATATACCTG 607212 kddkddkddkddkddk 0.40 372 55762 3 50016 TGCGGTTAACGATATA 607213 kddkddkddkddkddk 0.18 373 n/a n/a 50020 TGGGTGCGGTTAACGA 607214 kddkddkddkddkddk 1.39 374

TABLE 16 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01052 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 55466 0 49720 AAATTAATGGTAAGAG 607142 kddkddkddkddkddk 0.19 375 55470 0 49724 AGGCAAATTAATGGTA 607143 kddkddkddkddkddk 0.20 376 55474 0 49728 TGTTAGGCAAATTAAT 607144 kddkddkddkddkddk 0.53 377 55478 0 49732 TGTCTGTTAGGCAAAT 607145 kddkddkddkddkddk 0.59 378 55482 0 49736 TCAATGTCTGTTAGGC 607146 kddkddkddkddkddk 0.59 379 55486 0 49740 GCGATCAATGTCTGTT 607147 kddkddkddkddkddk 0.65 380 55490 0 49744 TAGGGCGATCAATGTC 607148 kddkddkddkddkddk 0.67 381 55494 0 49748 CCTTTAGGGCGATCAA 607149 kddkddkddkddkddk 0.68 382 55498 0 49752 CAGTCCTTTAGGGCGA 607150 kddkddkddkddkddk 0.68 383 55502 0 49756 ATGCCAGTCCTTTAGG 607151 kddkddkddkddkddk 0.71 384 55506 0 49760 GTGAATGCCAGTCCTT 607152 kddkddkddkddkddk 0.75 385 55510 0 49764 ATCAGTGAATGCCAGT 607153 kddkddkddkddkddk 0.75 386 55514 0 49768 CCACATCAGTGAATGC 607154 kddkddkddkddkddk 0.83 387 55518 0 49772 ACATCCACATCAGTGA 607155 kddkddkddkddkddk 0.84 388 55522 0 49776 ATCGACATCCACATCA 607156 kddkddkddkddkddk 0.88 389 55526 0 49780 TGGAATCGACATCCAC 607157 kddkddkddkddkddk 0.90 390 55530 0 49784 TTGATGGAATCGACAT 607158 kddkddkddkddkddk 0.91 391 55534 0 49788 AATTTTGATGGAATCG 607159 kddkddkddkddkddk 0.91 392 55538 0 49792 AAGCAATTTTGATGGA 607160 kddkddkddkddkddk 0.91 393 55542 0 49796 TCCCAAGCAATTTTGA 607161 kddkddkddkddkddk 0.95 394 55546 0 49800 GCTTTCCCAAGCAATT 607162 kddkddkddkddkddk 0.96 395 55550 0 49804 GTGGGCTTTCCCAAGC 607163 kddkddkddkddkddk 0.97 396 55554 0 49808 CCCTGTGGGCTTTCCC 607164 kddkddkddkddkddk 0.97 397 55558 0 49812 TTGCCCCTGTGGGCTT 607165 kddkddkddkddkddk 1.00 398 55562 0 49816 AAACTTGCCCCTGTGG 607166 kddkddkddkddkddk 1.06 399 55566 0 49820 CTGGAAACTTGCCCCT 607167 kddkddkddkddkddk 1.09 400 55570 0 49824 GTACCTGGAAACTTGC 607168 kddkddkddkddkddk 1.16 401 55574 0 49828 CCCTGTACCTGGAAAC 607169 kddkddkddkddkddk 1.17 402 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.16 308

TABLE 17 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01050 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.16 308 55578 0 49832 GTCACCCTGTACCTGG 607243 keekeekeekeekeek 0.83 331 55582 0 49836 GTAGGTCACCCTGTAC 607244 keekeekeekeekeek 0.97 332 55586 0 49840 TCGAGTAGGTCACCCT 607245 keekeekeekeekeek 0.27 333 55590 0 49844 GGGCTCGAGTAGGTCA 607246 keekeekeekeekeek 0.65 334 55594 0 49848 CTCAGGGCTCGAGTAG 607247 keekeekeekeekeek 0.71 335 55598 0 49852 CATCCTCAGGGCTCGA 607248 keekeekeekeekeek 0.85 336 55602 0 49856 ATTCCATCCTCAGGGC 607249 keekeekeekeekeek 0.59 337 55606 2 49860 CCGGATTCCATCCTCA 607250 keekeekeekeekeek 0.72 338 55610 2 49864 GCTCCCGGATTCCATC 607251 keekeekeekeekeek 0.52 339 55614 3 49868 AAAAGCTCCCGGATTC 607252 keekeekeekeekeek 0.38 340 48386 3 49872 AGGGAAAAGCTCCCGG 607253 keekeekeekeekeek 0.64 330 55622 1 49876 GTGCAGGGAAAAGCTC 607254 keekeekeekeekeek 0.61 341 55626 1 49880 TCAGGTGCAGGGAAAA 607255 keekeekeekeekeek 0.80 342 55630 0 49884 ACCATCAGGTGCAGGG 607256 keekeekeekeekeek 0.47 343 55634 0 49888 CTTCACCATCAGGTGC 607257 keekeekeekeekeek 0.83 344 55638 1 49892 TCGTCTTCACCATCAG 607258 keekeekeekeekeek 0.53 345 55642 1 49896 AGTGTCGTCTTCACCA 607259 keekeekeekeekeek 0.40 346 55646 1 49900 CTGCAGTGTCGTCTTC 607260 keekeekeekeekeek 0.84 347 55650 1 49904 AGCTCTGCAGTGTCGT 607261 keekeekeekeekeek 0.55 348 55654 1 49908 CTGCAGCTCTGCAGTG 607262 keekeekeekeekeek 0.93 349 55658 1 49912 GGCCCTGCAGCTCTGC 607263 keekeekeekeekeek 0.88 350 55662 1 49916 CTGAGGCCCTGCAGCT 607264 keekeekeekeekeek 0.87 351 55666 2 49920 CGGCCTGAGGCCCTGC 607265 keekeekeekeekeek 0.82 352 55670 2 49924 ACCCCGGCCTGAGGCC 607266 keekeekeekeekeek 0.46 353 55674 2 49928 TCAGACCCCGGCCTGA 607267 keekeekeekeekeek 0.84 354 55678 2 49932 GTACTCAGACCCCGGC 607268 keekeekeekeekeek 0.67 355 55682 1 49936 CTGTGTACTCAGACCC 607269 keekeekeekeekeek 0.78 356 55686 0 49940 CTGACTGTGTACTCAG 607270 keekeekeekeekeek 0.75 357 55690 0 49944 CACACTGACTGTGTAC 607271 keekeekeekeekeek 0.90 358 55694 0 49948 CAACCACACTGACTGT 607272 keekeekeekeekeek 0.41 359 55698 0 49952 AAGGCAACCACACTGA 607273 keekeekeekeekeek 0.30 360 55702 0 49956 GTGCAAGGCAACCACA 607274 keekeekeekeekeek 0.35 361 55706 0 49960 CATCGTGCAAGGCAAC 607275 keekeekeekeekeek 0.24 362 55710 0 49964 ATATCATCGTGCAAGG 607276 keekeekeekeekeek 0.24 363 55714 0 49968 CTCCATATCATCGTGC 607277 keekeekeekeekeek 0.20 364 55718 0 49972 GGCTCTCCATATCATC 607278 keekeekeekeekeek 0.35 365 55722 0 49976 GGCTGGCTCTCCATAT 607279 keekeekeekeekeek 0.84 366 55738 1 49992 CTGGATTCCAATCAGG 607280 keekeekeekeekeek 0.28 367 55742 1 49996 TGGACTGGATTCCAAT 607281 keekeekeekeekeek 0.54 368 55746 1 50000 CCTGTGGACTGGATTC 607282 keekeekeekeekeek 0.42 369 55750 0 50004 TATACCTGTGGACTGG 607283 keekeekeekeekeek 0.50 370 55754 1 50008 ACGATATACCTGTGGA 607284 keekeekeekeekeek 0.16 371 55758 2 50012 GTTAACGATATACCTG 607285 keekeekeekeekeek 0.18 372 55762 3 50016 TGCGGTTAACGATATA 607286 keekeekeekeekeek 0.20 373 n/a n/a 50020 TGGGTGCGGTTAACGA 607287 keekeekeekeekeek 1.28 374

TABLE 18 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01052 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.19 308 55466 0 49720 AAATTAATGGTAAGAG 607215 keekeekeekeekeek 0.55 375 55470 0 49724 AGGCAAATTAATGGTA 607216 keekeekeekeekeek 0.39 376 55474 0 49728 TGTTAGGCAAATTAAT 607217 keekeekeekeekeek 0.67 377 55478 0 49732 TGTCTGTTAGGCAAAT 607218 keekeekeekeekeek 0.87 378 55482 0 49736 TCAATGTCTGTTAGGC 607219 keekeekeekeekeek 0.74 379 55486 0 49740 GCGATCAATGTCTGTT 607220 keekeekeekeekeek 0.60 380 55490 0 49744 TAGGGCGATCAATGTC 607221 keekeekeekeekeek 0.59 381 55494 0 49748 CCTTTAGGGCGATCAA 607222 keekeekeekeekeek 0.71 382 55498 0 49752 CAGTCCTTTAGGGCGA 607223 keekeekeekeekeek 0.97 383 55502 0 49756 ATGCCAGTCCTTTAGG 607224 keekeekeekeekeek 0.83 384 55506 0 49760 GTGAATGCCAGTCCTT 607225 keekeekeekeekeek 1.00 385 55510 0 49764 ATCAGTGAATGCCAGT 607226 keekeekeekeekeek 1.09 386 55514 0 49768 CCACATCAGTGAATGC 607227 keekeekeekeekeek 0.84 387 55518 0 49772 ACATCCACATCAGTGA 607228 keekeekeekeekeek 0.96 388 55522 0 49776 ATCGACATCCACATCA 607229 keekeekeekeekeek 0.84 389 55526 0 49780 TGGAATCGACATCCAC 607230 keekeekeekeekeek 0.95 390 55530 0 49784 TTGATGGAATCGACAT 607231 keekeekeekeekeek 0.96 391 55534 0 49788 AATTTTGATGGAATCG 607232 keekeekeekeekeek 0.83 392 55538 0 49792 AAGCAATTTTGATGGA 607233 keekeekeekeekeek 0.65 393 55542 0 49796 TCCCAAGCAATTTTGA 607234 keekeekeekeekeek 0.73 394 55546 0 49800 GCTTTCCCAAGCAATT 607235 keekeekeekeekeek 0.96 395 55550 0 49804 GTGGGCTTTCCCAAGC 607236 keekeekeekeekeek 0.93 396 55554 0 49808 CCCTGTGGGCTTTCCC 607237 keekeekeekeekeek 0.99 397 55558 0 49812 TTGCCCCTGTGGGCTT 607238 keekeekeekeekeek 0.92 398 55562 0 49816 AAACTTGCCCCTGTGG 607239 keekeekeekeekeek 0.95 399 55566 0 49820 CTGGAAACTTGCCCCT 607240 keekeekeekeekeek 0.79 400 55570 0 49824 GTACCTGGAAACTTGC 607241 keekeekeekeekeek 0.68 401 55574 0 49828 CCCTGTACCTGGAAAC 607242 keekeekeekeekeek 0.84 402

TABLE 19 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01050 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.20 308 55578 0 49832 AGGTCACCCTGTACCTGG 607388 kkeekeekeekeekeeke 0.76 212 55582 0 49836 GAGTAGGTCACCCTGTAC 607389 kkeekeekeekeekeeke 0.76 216 55586 0 49840 GCTCGAGTAGGTCACCCT 607390 kkeekeekeekeekeeke 0.83 220 55590 0 49844 CAGGGCTCGAGTAGGTCA 607391 kkeekeekeekeekeeke 1.03 224 55594 0 49848 TCCTCAGGGCTCGAGTAG 607392 kkeekeekeekeekeeke 0.88 228 55598 0 49852 TCCATCCTCAGGGCTCGA 607393 kkeekeekeekeekeeke 0.74 232 55602 0 49856 GGATTCCATCCTCAGGGC 607394 kkeekeekeekeekeeke 1.16 236 55606 2 49860 TCCCGGATTCCATCCTCA 607395 kkeekeekeekeekeeke 0.81 240 55610 3 49864 AAGCTCCCGGATTCCATC 607396 kkeekeekeekeekeeke 0.71 244 55614 3 49868 GGAAAAGCTCCCGGATTC 607397 kkeekeekeekeekeeke 0.74 248 55618 3 49872 GCAGGGAAAAGCTCCCGG 607398 kkeekeekeekeekeeke 0.69 252 55622 1 49876 AGGTGCAGGGAAAAGCTC 607399 kkeekeekeekeekeeke 0.57 256 55626 1 49880 CATCAGGTGCAGGGAAAA 607400 kkeekeekeekeekeeke 0.80 260 55630 0 49884 TCACCATCAGGTGCAGGG 607401 kkeekeekeekeekeeke 0.64 264 55634 1 49888 GTCTTCACCATCAGGTGC 607402 kkeekeekeekeekeeke 0.65 268 55638 1 49892 TGTCGTCTTCACCATCAG 607403 kkeekeekeekeekeeke 0.46 272 55642 1 49896 GCAGTGTCGTCTTCACCA 607404 kkeekeekeekeekeeke 0.51 276 55646 1 49900 CTCTGCAGTGTCGTCTTC 607405 kkeekeekeekeekeeke 0.39 280 55650 1 49904 GCAGCTCTGCAGTGTCGT 607406 kkeekeekeekeekeeke 0.75 284 55654 1 49908 CCCTGCAGCTCTGCAGTG 607407 kkeekeekeekeekeeke 0.40 288 55658 1 49912 GAGGCCCTGCAGCTCTGC 607408 kkeekeekeekeekeeke 1.00 292 55662 2 49916 GCCTGAGGCCCTGCAGCT 607409 kkeekeekeekeekeeke 0.64 403 55666 2 49920 CCCGGCCTGAGGCCCTGC 607410 kkeekeekeekeekeeke 0.24 404 55670 2 49924 AGACCCCGGCCTGAGGCC 607411 kkeekeekeekeekeeke 0.47 405 55674 2 49928 ACTCAGACCCCGGCCTGA 607412 kkeekeekeekeekeeke 0.62 406 55678 2 49932 GTGTACTCAGACCCCGGC 607413 kkeekeekeekeekeeke 0.74 407 55682 1 49936 GACTGTGTACTCAGACCC 607414 kkeekeekeekeekeeke 0.53 408 55686 0 49940 CACTGACTGTGTACTCAG 607415 kkeekeekeekeekeeke 1.03 409 55690 0 49944 ACCACACTGACTGTGTAC 607416 kkeekeekeekeekeeke 0.95 410 55694 0 49948 GGCAACCACACTGACTGT 607417 kkeekeekeekeekeeke 0.83 411 55698 0 49952 GCAAGGCAACCACACTGA 607418 kkeekeekeekeekeeke 0.80 296 55702 0 49956 TCGTGCAAGGCAACCACA 607419 kkeekeekeekeekeeke 0.78 300 55706 0 49960 ATCATCGTGCAAGGCAAC 607420 kkeekeekeekeekeeke 0.88 412 55710 0 49964 CCATATCATCGTGCAAGG 607421 kkeekeekeekeekeeke 0.71 305 55714 0 49968 CTCTCCATATCATCGTGC 607422 kkeekeekeekeekeeke 0.84 309 55718 0 49972 CTGGCTCTCCATATCATC 607423 kkeekeekeekeekeeke 0.42 313 55738 1 49992 GACTGGATTCCAATCAGG 607424 kkeekeekeekeekeeke 0.47 413 55742 1 49996 TGTGGACTGGATTCCAAT 607425 kkeekeekeekeekeeke 0.49 414 55746 1 50000 TACCTGTGGACTGGATTC 607426 kkeekeekeekeekeeke 0.48 415 55750 1 50004 GATATACCTGTGGACTGG 607427 kkeekeekeekeekeeke 0.30 316 55754 1 50008 TAACGATATACCTGTGGA 607428 kkeekeekeekeekeeke 0.19 320 55758 3 50012 CGGTTAACGATATACCTG 607429 kkeekeekeekeekeeke 0.19 324 55762 3 50016 GGTGCGGTTAACGATATA 607430 kkeekeekeekeekeeke 0.41 328 n/a n/a 50020 GGTGGGTGCGGTTAACGA 607431 kkeekeekeekeekeeke 0.44 416

TABLE 20 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01052 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.19 308 55466 0 49720 GCAAATTAATGGTAAGAG 607360 kkeekeekeekeekeeke 0.51 417 55470 0 49724 TTAGGCAAATTAATGGTA 607361 kkeekeekeekeekeeke 0.53 418 55474 0 49728 TCTGTTAGGCAAATTAAT 607362 kkeekeekeekeekeeke 0.64 180 55478 0 49732 AATGTCTGTTAGGCAAAT 607363 kkeekeekeekeekeeke 1.06  32 55482 0 49736 GATCAATGTCTGTTAGGC 607364 kkeekeekeekeekeeke 0.85 184 55486 0 49740 GGGCGATCAATGTCTGTT 607365 kkeekeekeekeekeeke 1.12 185 55490 0 49744 TTTAGGGCGATCAATGTC 607366 kkeekeekeekeekeeke 0.44 189 55494 0 49748 GTCCTTTAGGGCGATCAA 607367 kkeekeekeekeekeeke 0.88 193 55498 0 49752 GCCAGTCCTTTAGGGCGA 607368 kkeekeekeekeekeeke 1.09 419 55502 0 49756 GAATGCCAGTCCTTTAGG 607369 kkeekeekeekeekeeke 1.04 420 55506 0 49760 CAGTGAATGCCAGTCCTT 607370 kkeekeekeekeekeeke 0.97 421 55510 0 49764 ACATCAGTGAATGCCAGT 607371 kkeekeekeekeekeeke 0.95 422 55514 0 49768 ATCCACATCAGTGAATGC 607372 kkeekeekeekeekeeke 1.05 423 55518 0 49772 CGACATCCACATCAGTGA 607373 kkeekeekeekeekeeke 1.04 424 55522 0 49776 GAATCGACATCCACATCA 607374 kkeekeekeekeekeeke 0.94 425 55526 0 49780 GATGGAATCGACATCCAC 607375 kkeekeekeekeekeeke 1.07 199 55530 0 49784 TTTTGATGGAATCGACAT 607376 kkeekeekeekeekeeke 1.05 426 55534 0 49788 GCAATTTTGATGGAATCG 607377 kkeekeekeekeekeeke 0.89 204 55538 0 49792 CCAAGCAATTTTGATGGA 607378 kkeekeekeekeekeeke 0.88 208 55542 0 49796 TTTCCCAAGCAATTTTGA 607379 kkeekeekeekeekeeke 0.97 427 55546 0 49800 GGGCTTTCCCAAGCAATT 607380 kkeekeekeekeekeeke 1.09 428 55550 0 49804 CTGTGGGCTTTCCCAAGC 607381 kkeekeekeekeekeeke 1.05 429 55554 0 49808 GCCCCTGTGGGCTTTCCC 607382 kkeekeekeekeekeeke 1.26 430 55558 0 49812 ACTTGCCCCTGTGGGCTT 607383 kkeekeekeekeekeeke 1.26 431 55562 0 49816 GGAAACTTGCCCCTGTGG 607384 kkeekeekeekeekeeke 1.07 432 55566 0 49820 ACCTGGAAACTTGCCCCT 607385 kkeekeekeekeekeeke 0.91 433 55570 0 49824 CTGTACCTGGAAACTTGC 607386 kkeekeekeekeekeeke 0.85 434 55574 0 49828 CACCCTGTACCTGGAAAC 607387 kkeekeekeekeekeeke 1.03 435

TABLE 21 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01050 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.15 308 55578 0 49832 AGGTCACCCTGTACCTGG 607316 kkddkddkddkddkddkk 0.47 212 55582 0 49836 GAGTAGGTCACCCTGTAC 607317 kkddkddkddkddkddkk 0.66 216 55586 0 49840 GCTCGAGTAGGTCACCCT 607318 kkddkddkddkddkddkk 0.78 220 55590 0 49844 CAGGGCTCGAGTAGGTCA 607319 kkddkddkddkddkddkk 0.78 224 55594 0 49848 TCCTCAGGGCTCGAGTAG 607320 kkddkddkddkddkddkk 0.60 228 55598 0 49852 TCCATCCTCAGGGCTCGA 607321 kkddkddkddkddkddkk 0.72 232 55602 0 49856 GGATTCCATCCTCAGGGC 607322 kkddkddkddkddkddkk 0.68 236 55606 2 49860 TCCCGGATTCCATCCTCA 607323 kkddkddkddkddkddkk 0.69 240 55610 3 49864 AAGCTCCCGGATTCCATC 607324 kkddkddkddkddkddkk 0.31 244 55614 3 49868 GGAAAAGCTCCCGGATTC 607325 kkddkddkddkddkddkk 0.58 248 55618 3 49872 GCAGGGAAAAGCTCCCGG 607326 kkddkddkddkddkddkk 0.52 252 55622 1 49876 AGGTGCAGGGAAAAGCTC 607327 kkddkddkddkddkddkk 0.28 256 55626 1 49880 CATCAGGTGCAGGGAAAA 607328 kkddkddkddkddkddkk 0.45 260 55630 0 49884 TCACCATCAGGTGCAGGG 607329 kkddkddkddkddkddkk 0.34 264 55634 1 49888 GTCTTCACCATCAGGTGC 607330 kkddkddkddkddkddkk 0.16 268 55638 1 49892 TGTCGTCTTCACCATCAG 607331 kkddkddkddkddkddkk 0.23 272 55642 1 49896 GCAGTGTCGTCTTCACCA 607332 kkddkddkddkddkddkk 0.18 276 55646 1 49900 CTCTGCAGTGTCGTCTTC 607333 kkddkddkddkddkddkk 0.17 280 55650 1 49904 GCAGCTCTGCAGTGTCGT 607334 kkddkddkddkddkddkk 0.41 284 55654 1 49908 CCCTGCAGCTCTGCAGTG 607335 kkddkddkddkddkddkk 0.44 288 55658 1 49912 GAGGCCCTGCAGCTCTGC 607336 kkddkddkddkddkddkk 0.42 292 55662 2 49916 GCCTGAGGCCCTGCAGCT 607337 kkddkddkddkddkddkk 0.23 403 55666 2 49920 CCCGGCCTGAGGCCCTGC 607338 kkddkddkddkddkddkk 0.14 404 55670 2 49924 AGACCCCGGCCTGAGGCC 607339 kkddkddkddkddkddkk 0.15 405 55674 2 49928 ACTCAGACCCCGGCCTGA 607340 kkddkddkddkddkddkk 0.15 406 55678 2 49932 GTGTACTCAGACCCCGGC 607341 kkddkddkddkddkddkk 0.22 407 55682 1 49936 GACTGTGTACTCAGACCC 607342 kkddkddkddkddkddkk 0.17 408 55686 0 49940 CACTGACTGTGTACTCAG 607343 kkddkddkddkddkddkk 0.39 409 55690 0 49944 ACCACACTGACTGTGTAC 607344 kkddkddkddkddkddkk 0.58 410 55694 0 49948 GGCAACCACACTGACTGT 607345 kkddkddkddkddkddkk 0.38 411 55698 0 49952 GCAAGGCAACCACACTGA 607346 kkddkddkddkddkddkk 0.43 296 55702 0 49956 TCGTGCAAGGCAACCACA 607347 kkddkddkddkddkddkk 0.56 300 55706 0 49960 ATCATCGTGCAAGGCAAC 607348 kkddkddkddkddkddkk 0.20 412 55710 0 49964 CCATATCATCGTGCAAGG 607349 kkddkddkddkddkddkk 0.22 305 55714 0 49968 CTCTCCATATCATCGTGC 607350 kkddkddkddkddkddkk 0.44 309 55718 0 49972 CTGGCTCTCCATATCATC 607351 kkddkddkddkddkddkk 0.29 313 55738 1 49992 GACTGGATTCCAATCAGG 607352 kkddkddkddkddkddkk 0.15 413 55742 1 49996 TGTGGACTGGATTCCAAT 607353 kkddkddkddkddkddkk 0.51 414 55746 1 50000 TACCTGTGGACTGGATTC 607354 kkddkddkddkddkddkk 0.23 415 55750 1 50004 GATATACCTGTGGACTGG 607355 kkddkddkddkddkddkk 0.24 316 55754 1 50008 TAACGATATACCTGTGGA 607356 kkddkddkddkddkddkk 0.21 320 55758 3 50012 CGGTTAACGATATACCTG 607357 kkddkddkddkddkddkk 0.14 324 55762 3 50016 GGTGCGGTTAACGATATA 607358 kkddkddkddkddkddkk 0.23 328 n/a n/a 50020 GGTGGGTGCGGTTAACGA 607359 kkddkddkddkddkddkk 0.25 416

TABLE 22 EDA ⁺FN mRNA levels compared to untreated cells (designated 1.00) in b.END cells measured with LTS01052 Mismatches Human to the Murine SEQ Start human Start ISIS ID Site sequence Site Sequence No Chemistry EDA + FN NO 55713 0 49967 TCTCCATATCATCGTGCA 606793 eeeeeeeeeeeeeeeeee 0.14 308 55466 0 49720 GCAAATTAATGGTAAGAG 607288 kkddkddkddkddkddkk 0.75 417 55470 0 49724 TTAGGCAAATTAATGGTA 607289 kkddkddkddkddkddkk 0.62 418 55474 0 49728 TCTGTTAGGCAAATTAAT 607290 kkddkddkddkddkddkk 0.47 180 55478 0 49732 AATGTCTGTTAGGCAAAT 607291 kkddkddkddkddkddkk 0.88  32 55482 0 49736 GATCAATGTCTGTTAGGC 607292 kkddkddkddkddkddkk 0.4  184 55486 0 49740 GGGCGATCAATGTCTGTT 607293 kkddkddkddkddkddkk 0.49 185 55490 0 49744 TTTAGGGCGATCAATGTC 607294 kkddkddkddkddkddkk 0.35 189 55494 0 49748 GTCCTTTAGGGCGATCAA 607295 kkddkddkddkddkddkk 0.53 193 55498 0 49752 GCCAGTCCTTTAGGGCGA 607296 kkddkddkddkddkddkk 0.66 419 55502 0 49756 GAATGCCAGTCCTTTAGG 607297 kkddkddkddkddkddkk 0.58 420 55506 0 49760 CAGTGAATGCCAGTCCTT 607298 kkddkddkddkddkddkk 0.67 421 55510 0 49764 ACATCAGTGAATGCCAGT 607299 kkddkddkddkddkddkk 0.67 422 55514 0 49768 ATCCACATCAGTGAATGC 607300 kkddkddkddkddkddkk 0.78 423 55518 0 49772 CGACATCCACATCAGTGA 607301 kkddkddkddkddkddkk 0.72 424 55522 0 49776 GAATCGACATCCACATCA 607302 kkddkddkddkddkddkk 0.65 425 55526 0 49780 GATGGAATCGACATCCAC 607303 kkddkddkddkddkddkk 0.84 199 55530 0 49784 TTTTGATGGAATCGACAT 607304 kkddkddkddkddkddkk 0.88 426 55534 0 49788 GCAATTTTGATGGAATCG 607305 kkddkddkddkddkddkk 0.62 204 55538 0 49792 CCAAGCAATTTTGATGGA 607306 kkddkddkddkddkddkk 0.78 208 55542 0 49796 TTTCCCAAGCAATTTTGA 607307 kkddkddkddkddkddkk 0.59 427 55546 0 49800 GGGCTTTCCCAAGCAATT 607308 kkddkddkddkddkddkk 0.61 428 55550 0 49804 CTGTGGGCTTTCCCAAGC 607309 kkddkddkddkddkddkk 1.08 428 55554 0 49808 GCCCCTGTGGGCTTTCCC 607310 kkddkddkddkddkddkk 1.13 430 55558 0 49812 ACTTGCCCCTGTGGGCTT 607311 kkddkddkddkddkddkk 1.14 431 55562 0 49816 GGAAACTTGCCCCTGTGG 607312 kkddkddkddkddkddkk 0.94 432 55566 0 49820 ACCTGGAAACTTGCCCCT 607313 kkddkddkddkddkddkk 0.65 433 55570 0 49824 CTGTACCTGGAAACTTGC 607314 kkddkddkddkddkddkk 0.68 434 55574 0 49828 CACCCTGTACCTGGAAAC 607315 kkddkddkddkddkddkk 0.77 435

Example 11: Dose-Dependent Antisense Inhibition of Fibronectin with Deoxy, MOE and (S)-cEt Antisense Oligonucleotides in b.END Cells

Antisense oligonucleotides from the studies described above exhibiting significant in vitro inhibition of EDA⁺FN mRNA were selected and tested at various doses in b.END cells. Cells were transfected using Cytofectin reagent with 0.19 nM, 0.39 nM, 0.78 nM, 1.56 nM, 3.125 nM, or 6.25 nM concentrations of antisense oligonucleotide, as specified in Tables 23-27. After a treatment period of approximately 16 hours, RNA was isolated from the cells and EDA⁺FN mRNA levels were measured by quantitative real-time PCR. Primer probe sets LTS01050 and LTS01052 were used to measure mRNA levels. EDA⁺FN mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. The results demonstrate blocking of splicing, as represented by EDA⁺FN expression. The expression value of untreated cells was taken as 1.00. Different primer probe sets were used for different antisense oligonucleotide-treated cells to avoid the amplicon effect. Each table represents a separate experiment.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Tables 23-27. As illustrated in the tables, EDA⁺FN mRNA levels were significantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

TABLE 23 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by 16-mer MOE, deoxy and (S)-cEt antisense oligonucleotides in b.END cells measured with LTS01050 0.19 0.39 0.78 ISIS No nM nM nM 1.56 nM 3.125 nM 6.25 nM IC₅₀ 607178 0.7 0.6 0.5 0.3 0.2 0.1 0.59 607186 0.6 0.5 0.4 0.2 0.2 0.1 0.39 607188 0.8 0.6 0.4 0.3 0.2 0.1 0.67 607204 0.6 0.4 0.3 0.2 0.1 0.1 0.27 607205 0.6 0.5 0.4 0.3 0.2 0.1 0.34 607207 0.5 0.4 0.3 0.2 0.1 0.1 0.21 607208 0.9 0.5 0.4 0.3 0.2 0.2 0.62 607209 0.7 0.6 0.5 0.3 0.3 0.2 0.68 607210 0.8 0.6 0.5 0.3 0.3 0.2 0.77

TABLE 24 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by 16-mer MOE, deoxy and (S)-cEt antisense oligonucleotides in b.END cells measured with LTS01052 0.19 0.39 0.78 ISIS No nM nM nM 1.56 nM 3.125 nM 6.25 nM IC₅₀ 607148 0.6 0.5 0.6 0.4 0.2 0.1 0.60 607149 0.7 0.5 0.3 0.3 0.1 0.1 0.44

TABLE 25 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by 18-mer MOE, deoxy and (S)-cEt antisense oligonucleotides in b.END cells measured with LTS01050 0.19 0.39 0.78 ISIS No nM nM nM 1.56 nM 3.125 nM 6.25 nM IC₅₀ 607330 0.6 0.4 0.3 0.2 0.2 0.1 0.28 607332 0.6 0.5 0.3 0.2 0.1 0.1 0.35 607333 0.6 0.6 0.5 0.3 0.2 0.2 0.59 607338 0.8 0.9 0.8 0.7 0.5 0.4 3.64 607339 0.8 0.8 0.7 0.6 0.6 0.5 5.89 607340 0.7 0.6 0.5 0.3 0.3 0.2 0.63 607341 0.6 0.5 0.4 0.3 0.2 0.1 0.44 607342 0.9 0.7 0.5 0.5 0.4 0.4 1.54 607348 0.9 0.7 0.5 0.3 0.2 0.2 0.96 607352 0.4 0.4 0.2 0.1 0.1 0.1 0.16 607357 0.7 0.5 0.4 0.2 0.2 0.1 0.48

TABLE 26 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by 16-mer MOE, deoxy and (S)-cEt antisense oligonucleotides in b.END cells measured with LTS01050 0.19 0.39 0.78 ISIS No nM nM nM 1.56 nM 3.125 nM 6.25 nM IC₅₀ 607245 0.9 0.9 0.5 0.5 0.4 0.4 2.04 607275 0.8 0.8 0.5 0.5 0.2 0.2 1.09 607276 0.8 0.6 0.4 0.3 0.2 0.2 0.57 607277 0.7 0.6 0.4 0.2 0.2 0.1 0.48 607284 0.6 0.6 0.3 0.1 0.1 0.1 0.37 607285 0.4 0.4 0.2 0.1 0.1 0.1 0.12 607286 0.7 0.4 0.3 0.2 0.1 0.1 0.36

TABLE 27 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by MOE, deoxy and (S)-cEt antisense oligonucleotides in b.END cells measured with LTS01050 Length 0.19 0.39 0.78 1.56 3.125 ISIS No (nt) nM nM nM nM nM 6.25 nM IC₅₀ 607428 18 0.5 0.3 0.1 0.1 0.1 0.1 0.16 607429 18 0.6 0.7 0.5 0.3 0.2 0.1 0.58 607213 16 0.9 0.8 0.5 0.3 0.2 0.2 0.95

Example 12: Dose-Dependent Antisense Inhibition of Fibronectin with Uniform MOE Antisense Oligonucleotides in b.END Cells

Antisense oligonucleotides from the studies described above exhibiting significant in vitro inhibition of EDA⁺FN mRNA were selected and tested at various doses in b.END cells. Cells were transfected using Cytofectin reagent with 0.39 nM, 0.78 nM, 1.56 nM, 3.125 nM, 6.25 nM or 12.5 nM concentrations of antisense oligonucleotide, as specified in Tables 28-31. After a treatment period of approximately 16 hours, RNA was isolated from the cells and EDA⁺FN mRNA levels were measured by quantitative real-time PCR. Primer probe sets LTS01050 and LTS01052 were used to measure mRNA levels. EDA⁺FN mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. The results demonstrate blocking of splicing, as represented by EDA⁺FN expression. The expression value of untreated cells was taken as 1.00. Different primer probe sets were used for different antisense oligonucleotide-treated cells to avoid the amplicon effect. Each table represents a separate experiment.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Tables 28-31. As illustrated in the tables, EDA⁺FN mRNA levels were significantly reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

TABLE 28 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by 18-mer uniform MOE oligonucleotides in b.END cells measured with LTS01050 0.39 0.78 1.56 ISIS No nM nM nM 3.125 nM 6.25 nM 12.5 nM IC₅₀ 606708 1.1 0.8 0.6 0.4 0.3 0.2 2.79 606723 0.8 0.8 0.6 0.4 0.2 0.1 2.39 606729 0.8 0.6 0.3 0.2 0.1 0.1 1.10 606753 0.8 0.5 0.4 0.3 0.2 0.1 1.09 606770 0.7 0.5 0.4 0.2 0.1 0.1 0.87 606785 0.5 0.3 0.2 0.1 0.1 0.1 0.37 606787 0.5 0.3 0.3 0.1 0.1 0.1 0.30 606788 0.4 0.2 0.2 0.1 0.1 0.1 0.21 606793 0.3 0.3 0.2 0.1 0.1 0.1 0.09 606804 0.5 0.3 0.3 0.1 0.1 0.1 0.40 606812 0.4 0.3 0.2 0.1 0.1 0.1 0.23

TABLE 29 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by ISIS 606675 in b.END cells measured with LTS01052 0.39 nM 0.8 0.78 nM 0.6 1.56 nM 0.5 3.125 nM  0.3 6.25 nM 0.1 12.5 nM 0.1 IC₅₀ 1.38

TABLE 30 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by 15-mer uniform MOE oligonucleotides in b.END cells measured with LTS01050 0.39 0.78 1.56 ISIS No nM nM nM 3.125 nM 6.25 nM 12.5 nM IC₅₀ 598137 1.0 0.8 0.7 0.5 0.4 0.2 4.08 598138 0.8 0.9 0.6 0.6 0.4 0.2 4.11 598144 0.9 0.7 0.4 0.4 0.2 0.1 1.75 598151 0.7 0.5 0.3 0.2 0.1 0.1 0.79 598153 0.9 0.6 0.5 0.3 0.2 0.1 1.54 598161 0.9 0.5 0.5 0.3 0.2 0.2 1.50 598163 0.6 0.5 0.4 0.3 0.1 0.1 0.60 594675 0.8 0.6 0.4 0.3 0.1 0.1 1.18 598145 0.9 0.7 0.5 0.3 0.2 0.1 1.58

TABLE 31 EDA⁺FN mRNA levels compared to untreated cells (designated 1.00) by 15-mer uniform MOE oligonucleotides in b.END cells measured with LTS01052 0.39 0.78 1.56 ISIS No nM nM nM 3.125 nM 6.25 nM 12.5 nM IC₅₀ 511404 0.9 0.8 0.7 0.4 0.3 0.2 2.81 598130 0.9 1.0 0.9 0.9 0.7 0.5 13.18

Example 13: Efficacy and Tolerability of Antisense Oligonucleotides Targeting Fibronectin in C57BL/6 Mice

C57BL/6 mice are a multipurpose mice model, frequently utilized for safety and efficacy testing. The mice were treated with ISIS antisense oligonucleotides selected from studies described above and evaluated for efficacy, as well as changes in the levels of various plasma chemistry markers.

Study with Uniform MOE Oligonucleotides

Treatment

Groups of eight-week old C57BL/6 mice were injected subcutaneously twice a week for 3 weeks with 100 mg/kg of ISIS 594675, ISIS 598145, ISIS 598151, ISIS 598153, ISIS 598163, ISIS 606770, ISIS 606785, ISIS 606787, ISIS 606788, ISIS 606793, ISIS 606804, or ISIS 606812. One group of eight-week old C57BL/6 mice was injected subcutaneously twice a week for 3 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further analysis.

RNA Analysis

To evaluate the effect of ISIS oligonucleotides on blocking fibronectin splicing, mRNA levels of EDA⁺FN were measured by RT-PCR using mouse primer probe set LTS01050 and LTS01052. The results are presented in Table 32, normalized to total fibronectin. The results demonstrate blocking of splicing, as represented by EDA⁺FN expression. The expression value in untreated mice was taken as 1.00. ‘n.d.’ indicates that the mRNA expression level values were not considered because the oligonucleotide targeted an amplicon region of the specific primer probe set.

TABLE 32 EDA⁺FN expression after antisense oligonucleotide treatment in C57BL/6 mice Lungs Kidneys EDA⁺FN/ EDA⁺FN/ EDA⁺FN/ EDA⁺FN/ total FN total FN total FN total FN ISIS No (LTS01050) (LTS01052) (LTS01050) (LTS01052) 594675 0.43 0.43 0.52 0.57 598145 0.65 0.61 0.61 0.64 598151 0.40 0.33 0.43 0.36 598153 0.75 0.57 1.07 0.69 598163 0.24 0.23 0.15 0.17 606770 0.50 0.38 0.54 0.52 606785 0.31 0.33 0.22 0.29 606787 0.36 0.32 0.26 0.32 606788 0.40 0.36 0.19 0.22 606793 0.28 0.23 0.12 0.14 606804 0.32 n.d. 0.27 n.d. 606812 0.39 n.d. 0.42 n.d.

Plasma Chemistry Markers

To evaluate the effect of ISIS oligonucleotides on liver and kidney function, plasma levels of transaminases, bilirubin, albumin, and BUN were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). The results are presented in Table 33. ISIS oligonucleotides did not cause any changes in the levels of any of the liver or kidney function markers outside the expected range for antisense oligonucleotides.

TABLE 33 Plasma chemistry markers in C57BL/6 mice plasma ALT AST Bilirubin BUN (IU/L) (IU/L) (mg/dL) (mg/dL) PBS 26 46 0.19 35 ISIS 594675 19 42 0.20 31 ISIS 598145 25 49 0.20 29 ISIS 598151 30 67 0.18 35 ISIS 598153 26 71 0.17 34 ISIS 598163 64 102 0.19 38 ISIS 606770 22 54 0.18 29 ISIS 606785 48 94 0.17 32 ISIS 606787 30 71 0.15 30 ISIS 606788 82 116 0.15 33 ISIS 606793 50 83 0.15 32 ISIS 606804 31 56 0.16 28 ISIS 606812 29 49 0.15 27

Organ Weights

Liver, spleen and kidney weights were measured at the end of the study, and are presented in Table 34. ISIS oligonucleotides did not cause any changes in organ weights outside the expected range for antisense oligonucleotides.

TABLE 34 Organ weights (% of the PBS control) of C57BL/6 mice ISIS No Liver Kidneys Spleen 594675 102 102 99 598145 98 105 117 598151 108 103 90 598153 106 100 88 598163 102 102 94 606770 106 104 93 606785 101 102 98 606787 108 99 93 606788 98 97 99 606793 103 94 99 606804 95 98 89 606812 105 101 86 Study with Deoxy, (S)-cEt and MOE Oligonucleotides

Treatment

Groups of eight-week old C57BL/6 mice were injected subcutaneously twice a week for 3 weeks with 100 mg/kg of ISIS 607149, ISIS 607186, ISIS 607204, ISIS 607205, ISIS 607207, ISIS 607277, ISIS 607285, ISIS 607286, ISIS 607330, ISIS 607332, ISIS 607341, ISIS 607352, ISIS 607428, or ISIS 607429. One group of eight-week old C57BL/6 mice was injected subcutaneously twice a week for 3 weeks with PBS. Mice were euthanized 48 hours after the last dose, and organs and plasma were harvested for further analysis.

RNA Analysis

To evaluate the effect of ISIS oligonucleotides on blocking fibronectin splicing, mRNA levels of EDA⁺FN were measured by RT-PCR using mouse primer probe set LTS01050 and LTS01052. The results are presented in Table 35, normalized to total fibronectin. The results demonstrate blocking of splicing, as represented by EDA⁺FN expression. The expression value in untreated mice was taken as 1.00. ‘n.d.’ indicates that the mRNA expression level values were not considered because the oligonucleotide targeted an amplicon region of the specific primer probe set.

TABLE 35 EDA⁺FN expression after antisense oligonucleotide treatment in C57BL/6 mice Lungs Kidneys EDA⁺FN/ EDA⁺FN/ EDA⁺FN/ EDA⁺FN/ total FN total FN total FN total FN ISIS No (LTS01050) (LTS01052) (LTS01050) (LTS01052) 607149 n.d. 0.32 n.d. 0.07 607186 0.26 0.14 0.02 0.02 607204 0.15 0.13 0.02 0.03 607205 0.30 n.d. 0.03 n.d. 607207 0.42 n.d. 0.04 n.d. 607277 0.33 0.27 0.05 0.08 607285 0.21 n.d. 0.29 n.d. 607286 0.13 n.d. 0.02 n.d. 607330 0.29 0.27 0.02 0.06 607332 0.08 0.13 0.01 0.05 607341 0.15 0.24 0.10 0.16 607352 0.11 n.d. 0.01 n.d. 607357 0.12 n.d. 0.09 n.d. 607428 0.12 n.d. 0.07 n.d. 607429 0.33 n.d. 0.20 n.d.

Plasma Chemistry Markers

To evaluate the effect of ISIS oligonucleotides on liver and kidney function, plasma levels of transaminases, bilirubin, albumin, and BUN were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). The results are presented in Table 36. ISIS oligonucleotides that caused any changes in organ weights outside the expected range for antisense oligonucleotides were excluded from further studies.

TABLE 36 Plasma chemistry markers in C57BL/6 mice plasma ALT AST Bilirubin BUN (IU/L) (IU/L) (mg/dL) (mg/dL) PBS 38 96 0.18 36 ISIS 607149 35 170 0.29 31 ISIS 607186 22 73 0.21 26 ISIS 607204 41 75 0.15 29 ISIS 607205 38 83 0.15 32 ISIS 607207 70 92 0.19 32 ISIS 607277 54 108 0.16 30 ISIS 607285 78 139 0.32 28 ISIS 607286 40 94 0.38 27 ISIS 607330 23 40 0.16 30 ISIS 607332 41 66 0.20 28 ISIS 607341 70 102 0.24 28 ISIS 607352 20 75 0.13 27 ISIS 607357 85 100 0.15 26 ISIS 607428 21 82 0.24 25 ISIS 607429 21 50 0.17 26

Organ Weights

Liver, spleen and kidney weights were measured at the end of the study, and are presented in Table 37. ISIS oligonucleotides that caused any changes in organ weights outside the expected range for antisense oligonucleotides were excluded from further studies.

TABLE 37 Organ weights (% of the PBS control) of C57BL/6 mice ISIS No. Liver Kidneys Spleen 607149 103 103 99 607186 91 106 101 607204 93 97 116 607205 112 114 276 607207 98 99 96 607277 98 100 108 607285 99 97 105 607286 96 103 98 607330 97 101 85 607332 102 98 97 607341 93 98 92 607352 98 101 84 607357 88 101 113 607428 96 101 90 607429 91 101 99 

1. A compound comprising a modified oligonucleotide consisting of 18 to 20 linked nucleosides and having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length of a fibronectin transcript, wherein the target region is within nucleobase 55441 and nucleobase 55790 of SEQ ID NO:
 1. 2. The compound of claim 1, wherein the complementary region of the modified oligonucleotide is 100% complementary to the target region. 3-118. (canceled)
 119. The compound of claim 1, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.
 120. The compound of claim 119, comprising at least one phosphorothioate internucleoside linkage.
 121. The compound of claim 1, wherein the modified oligonucleotide comprises at least one 2′-substituted sugar moiety.
 122. The compound of claim 121, wherein the 2′-substituted sugar moiety is selected from a group consisting of 2′-MOE, 2′-OMe, and 2′-F.
 123. The compound of claim 121, wherein the 2′-substituted sugar moiety is a 2′-MOE.
 124. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 